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Abstract 
Purines and related heterocycles substituted at C-2 with 4’-sulfamoylanilino and at C-6 with a 
variety of groups have been synthesized with the aim of achieving selectivity of binding to CDK2 
over CDK1. 6-Substituents that favour competitive inhibition at the ATP binding site of CDK2 
were identified and typically exhibited 10-80-fold greater inhibition of CDK2 compared to CDK1. 
Most impressive was 4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide (73) 
that exhibited high potency towards CDK2 (IC50 0.044 µM), but was ~ 2000-fold less active 
towards CDK1 (IC50 86 µM). This compound is therefore a useful tool for studies of cell cycle 
regulation. Crystal structures of inhibitor-kinase complexes showed that the inhibitor stabilizes a 
glycine-rich loop conformation that shapes the ATP ribose binding pocket, and that is preferred in 
CDK2, but has not been observed in CDK1. This aspect of the active site may be exploited for the 
design of inhibitors that distinguish between CDK1 and CDK2.  
 
Key words 
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Introduction 
The cyclin-dependent kinase (CDK) family of serine/threonine kinases plays an integral role in the 
regulation of the eukaryotic cell cycle, as well as having key functions in apoptosis, transcription, 
differentiation and neuronal function. 1, 2 Deregulation of the cell cycle, a hallmark of human 
cancer, is frequently associated with aberrant CDK activity through mechanisms that may include 
mutation/overexpression of CDKs, or mutations to genes encoding proteins that directly or 
indirectly modulate CDK activity. 3-5 CDK2 activation entails association with partner cyclins A 
and E, whereas the endogenous proteins p21Cip1 and p27Kip1 are inhibitory. Cyclin E overexpression 
and/or p27Kip1 suppression are a common feature of many human tumors. 6, 7 
 
Pharmacological inhibition of CDK family members is a potential therapeutic approach for the 
treatment of cancer. In this context, a large number of ATP-competitive inhibitors have been 
evaluated. 5-9 The clinical development of CDK inhibitors as antitumour agents was originally 
hampered by poor kinase selectivity, particularly within the CDK family, and uncertainty as to 
which CDK constitutes the most appropriate therapeutic target. 3 However, an appreciation of the 
roles played by specific CDKs in sustaining signalling through dysregulated pathways that drive 
particular cancers is leading to more stringent patient selection and correspondingly improved 
efficacy. For example, the highly selective CDK4/6 inhibitor palbociclib has been approved for the 
treatment of ER-positive, HER2-negative breast cancer, while abemaciclib, palbociclib and 
ribociclib are in Phase III clinical trials to treat advanced breast cancer in which signalling through 
the CDK4/6-retinoblastoma axis is critical. 10 Similarly, agents that target a subset of CDKs are 
being evaluated in a range of other clinically defined segments. 11 
 
The validity of CDK2 as a cancer therapeutic target was originally called into question both by 
CDK2 knockdown experiments in which loss of CDK2 failed to induce cell cycle arrest in a number 
of tumour cell lines, 12 and by mouse knockout experiments where the animals were viable. 13, 14 
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However, applying the rationale outlined above, CDK2 inhibitors are also expected to have utility 
in settings in which the cancer is addicted to enhanced CDK2 activity or where synthetic lethalities 
can be identified. Recent studies employing a chemical genetic approach in which CDK2 
expression was maintained, but kinase activity was inhibited, provides compelling evidence that 
CDK2 is a valid cancer target. In a panel of human cancer cells transformed with various 
oncogenes, highly selective small-molecule CDK2 inhibition resulted in marked growth inhibition. 
15 CDK2-selective inhibitors may also have applications in combination therapies in appropriate 
clinical settings.  For example, a recent study demonstrated that a combination of 
phosphatidylinositol-3-kinase and CDK2 inhibitors induced apoptosis in malignant glioma 
xenografts via a synthetic-lethal interaction. 16  Accumulating evidence also implicates CDK2 as a 
prospective therapeutic target in BRCA-deficient cancers, 17 neuroblastoma 18 and ovarian cancer. 19 
These observations, taken together with supportive clinical data, 20 have led to a resurgence of 
interest in CDK2 inhibitors as cancer therapeutic agents. 21, 22 Ideally, such an inhibitor would 
discriminate between CDK2 and CDK1 to avoid cell toxicity as a result of inhibiting CDK1 which 
is an essential member of the CDK family. 
 
 
 
Our previous studies employing a structure-lead approach resulted in the development of selective 
ATP-competitive CDK2 inhibitors based on 2-amino-6-alkoxy- (1; NU2058) and 2-arylamino-6-
alkoxy- (2) purine derivatives. 23, 24 These efforts were rewarded by the identification of potent 
purine-based inhibitors, exemplified by 6-cyclohexylmethoxy-2-(4’-sulfamoylanilino)purine (3; 
NU6102, CDK2 IC50 = 5.0 nM), 
25 as well as alkoxypyrimidine inhibitors (e.g. 4, CDK2 IC50 = 0.8 
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nM). 26 Importantly, 3 exhibits selectivity for CDK2 over other CDK-family members, proving 
some 50-fold selective for CDK2 over CDK1 (IC50 = 250 nM), a kinase with close structural 
homology to CDK2. In addition, 3 is only weakly active against CDK7 and CDK9 (IC50 = 4.4 µM 
and 1.1 µM, respectively). These CDKs play a key role in transcriptional regulation through 
phosphorylation of RNA polymerase II. 2, 27 Modulation of protein synthesis by off-target inhibition 
of CDK7/CDK9 has obfuscated previous studies to elucidate the pharmacological effects of 
clinically evaluated compounds initially identified as selective CDK2 inhibitors such as seliciclib 
(5), dinaciclib (6) and SNS-032 (7). 3, 28, 29 
 
 
Crystal structures of purines 1-3 in complex with T160-phosphorylated CDK2-cyclin A (CDK2-
cyclin A) provided valuable details of inhibitor interactions within the ATP-binding site. 23, 24 The 
purine heterocycle anchors the inhibitor through a triplet of hydrogen bonds between N-9, N-3, and 
the 2-amino group, and the backbone carbonyl moiety of Glu81 and amide and carbonyl moieties of 
Leu83, respectively, located in the hinge region of the kinase (Figure 2). The greater potency and 
selectivity of 3 compared with 2 and the parent 2-amino-6-cyclohexylmethoxypurine 1, has been 
attributed, at least in part, to additional interactions of the 2-sulfanilyl substituent of 3 with the 
specificity surface of CDK2. 24, 30 Notably, two hydrogen bond interactions between the 
sulfonamide group of 3 and Asp86 facilitate optimal hydrophobic packing of the arylamino ring. 
 
Extensive structure-activity relationship studies (SARs) at the purine 2-position of 3 have further 
established the importance of these inhibitor-kinase interactions. 25 By contrast, although the 6-
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cyclohexylmethyl group of 3 occupies the ribose-binding pocket, the precise nature of the 
interactions made by substituents at the purine 6-position with the CDK2 active site remains 
uncertain, notwithstanding that a large number of derivatives have previously been evaluated 
empirically. 31 
 
In this paper, we report the results of studies to characterise interactions between substituents at the 
purine 6-position and the CDK2 ATP-binding site. The effect upon biological activity of modifying 
the core purine heterocycle of 3 is also reported. These studies have resulted in the identification of 
4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide 73 as a potent and selective 
CDK2 inhibitor (IC50 = 44 nM), exhibiting some 2,000-fold-selectivity over CDK1 (IC50 = 86 µM). 
 
Chemistry 
With a view to establishing the overall contribution of the 6-cyclohexylmethoxy substituent of 1 
and 3 to inhibitor binding, the simple 6-unsubstituted purines 8, 12 and 13 were required. 2-
aminopurine (8) was commercially available, while the 2-phenylaminopurine (12) and 2-
sulfanilylpurine (13) derivatives were synthesised as outlined in Scheme 1. Thus, selective 
reductive dehalogenation of 6-chloro-2-fluoropurine (10), prepared from 2-amino-6-chloropurine 
(9) following a literature procedure, 32 afforded 2-fluoropurine (11). Treatment of 11 with aniline or 
4-aminobenzenesulfonamide (sulfanilamide) in 2,2,2-trifluoroethanol (TFE) with catalysis by 
trifluoroacetic acid (TFA) as described previously, 33 gave the respective 2-arylaminopurines 12 and 
13 in good yield. The required 2-arylaminoguanine derivatives 15 and 16 were also readily 
accessible from commercially available 2-bromohypoxanthine (14) under similar conditions. The 6-
alkoxypurine derivatives (30-35) were synthesised utilising previously optimised methodology. 23, 
25, 31 Briefly, introduction of the 6-alkoxy substituent was achieved either by direct reaction of the 
appropriate sodium alkoxide with 2-amino-6-chloropurine (9) employing the corresponding alcohol 
as solvent, or, where necessary, following conversion into the ‘DABCO-purine’ intermediate (17).34 
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Elaboration of the 6-alkoxy-2-aminopurines (18-23) into the corresponding 2-fluoropurines (24-29) 
under Balz-Schiemann conditions, enabled subsequent introduction of the 2-(4-
aminobenzenesulfonamide) group using the TFA-TFE procedure, to furnish the target purines (30-
35) in good overall yields (Scheme 1). 
 
Scheme 1. Reagents and conditions – (i) aq. HBF4, NaNO2, -15-0 °C; (ii) Pd(OH)2, HCO2NH4, 
MeOH, reflux; (iii) ArNH2, TFA, TFE, 90 ºC; (iv) POCl3, PhNMe2, reflux; (v) 3,4-dihydropyran, 
(rac)-camphorsulfonic acid, EtOAc, 75 °C; (vi) R-CCH, PdCl2(MeCN)2, dicyclohexyl-(2',4',6'-
triisopropyl-[1,1'-biphenyl]-2-yl)phosphine, Cs2CO3, MeCN; (vii) TFA, i-PrOH, H2O, reflux; (viii) 
DABCO, DMSO, 25 °C; (ix) For 18, 19, 22: ROH, Na, reflux, For 20, 21, 23: ROH, NaH, DMSO, 
25 ºC. For definition of R groups see Table 1. 
 
The 6-ethynylpurine derivatives (41 and 42) were synthesised from the THP-protected 6-chloro-2-
fluoropurine (36) 35 via a Sonogashira alkynylation approach (Scheme 2). Coupling of 
triisopropylacetylene with 36, employing Pd(PPh3)2Cl2/CuI, afforded the protected 6-ethynylpurine 
(37) in excellent yield, and removal of the N9-THP group to give 38 and introduction of the 2-
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arylamino substituent, proceeded in the manner described above to give 39 and 40. Removal of the 
TIPS group to furnish the target 2-arylamino-6-ethynylpurines 41 and 42 was achieved under 
standard conditions. The 6-propynyl- and 6-phenylethynyl-purine derivatives 48 and 49 were 
accessible from the guanine derivative 15 by sequential chlorination at the purine 6-position (44), 
THP protection (45), introduction of the appropriately substituted ethynyl group under Sonogashira 
conditions (46, 47) and final N9-deprotection to furnish the target purines 48 and 49 (Scheme 1). 
The 6-ethylpurine derivative (52) was readily obtained by reduction of the 6-ethynyl group of the 
THP derivative 43 with Lindlar’s catalyst-quinoline to afford 50, with N9-deprotection (51) and 
final introduction of the 2-(4-aminobenzenesulfonamide) group giving 52 in modest overall yield. 
 
Scheme 2. Reagents and conditions – (i) 3,4-dihydropyran, (rac)-camphorsulfonic acid, EtOAc, 
75 °C; (ii) (i-Pr)3SiCCH, Pd(PPh3)Cl2, CuI, Et3N, THF, 25 ºC; (iii) TFA, i-PrOH, H2O, reflux; (iv) 
PhNH2 or 4-NH2C6H4SO2NH2, TFA, TFE, 90 ºC; (v) (n-Bu)4NF, THF, 25 ºC; (vi) Lindlar’s 
catalyst, quinoline, H2, EtOAc, RT, 2 h; (vii) RB(OH)2 or RBF3K, Pd(OAc)2, dicyclohexyl(2',6'-
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dimethoxybiphenyl-2-yl)phosphine, K3PO4, PhMe, H2O, 100 ºC. For definition of R groups see 
Table 1. 
 
Efforts to synthesise the 6-cyclopropylpurine (55) employing Suzuki-Miyaura conditions were 
unsuccessful, likely due to competing protodeboronation of the cyclopropylboronic acid under the 
reaction conditions employed. This problem was successfully addressed as reported in the literature, 
by converting the cyclopropylboronic acid into the corresponding potassium trifluoroborate, 36 
whereby coupling to the THP-protected 6-chloro-2-fluoropurine (36) occurred to furnish 53 in 
acceptable yield. Subsequent transformation into the target 6-cyclopropylpurine (55) was achieved 
readily. The introduction of aryl substituents at the purine 6-position was achieved using Suzuki-
Miyaura cross-coupling chemistry with 6-chloro-2-fluoropurine derivative 36 (Scheme 2). 
Optimisation of the reagents and reaction conditions employed for the cross-coupling step, enabled 
the preparation of a defined series of 2-fluoro-6-arylpurine derivatives (56-62) in excellent yields, 
and conversion into the requisite 6-aryl-2-(4-sulfonamidophenyl)aminopurines (70-76) proceeded 
smoothly under the previously described conditions. 25, 33 
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Scheme 3. Reagents and conditions – (i) PMB-Cl, K2CO3, DMF, 80 ºC; (ii) NaH, 
cyclohexylmethanol, DMSO, 25 ºC; (iii) TFA, 80 ºC; (iv) CH2I2, iso-amyl nitrite, CuI, THF, 80 ºC; 
(v) sulfanilamide, Pd2(dba)3, XPhos, K2CO3, MeCN, 80 ºC; (vi) LiCl, iso-amyl nitrite, SOCl2, DMA 
or THF, 0 ºC - 25 ºC; (vii) ArNH2, TFA, TFE, 90 ºC; (viii) SEM-Cl, NaH, MeCN, 0 ºC; (ix) TBAF, 
THF, 25 ºC. 
 
The synthesis of prospective CDK2 inhibitors encompassing alternative heterocyclic systems was 
undertaken as summarised in Scheme 3. In each case, the parent chloroheterocycles (77, 84, 85, 92, 
99) were synthesised by adapting literature procedures 37-41 and the cyclohexylmethyl substituent 
introduced by treatment with the corresponding alkoxide, with N9 protected where necessary, as 
described previously. Iodination (81) 42 or chlorination (88, 89, 96) of the respective 2-
aminoheterocycles under Sandmeyer conditions facilitated introduction of the 2-arylamino group 
under the standard TFA-TFE conditions (88, 89), or employing a Buchwald amination procedure 
(81, 96), followed by deprotection as necessary to afford the target compounds 83, 90, 91, and 98. 
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The imidazo[1,2-a]pyrimidine derivatives (101, 102) were prepared from 5,7-dichloroimidazo[1,2-
a]pyrimidine (99) 43, 44 by regioselective 5-alkoxylation to give 100, followed by final introduction 
of the arylamino group at the 7-position under TFA-TFE conditions. Given the possibility of 
alkoxide attack at the 7-position of 99 to furnish the alternative regioisomer, the structure of 102 
was unambiguously confirmed by X-ray crystallography (Supporting Information). 
 
Results and Discussion 
The chemical structures, CDK-inhibitory activity, and in vitro antitumor activity for the purine 
derivatives and alternative heterocycles are summarised in Tables 1-3, with the values for 
compounds 1-3 included for comparative purposes. 
Structure-Activity Relationships – The importance of a substituent at the purine 6-position was 
reaffirmed by the simple 2-amino- and 2-phenylamino-purines (8 and 12), where a dramatic 
reduction in potency was observed compared with the parent 6-cyclohexylmethoxy derivatives 1 
and 2, respectively. A similar effect was also evident for the sulfanilylpurine 13, which was some 
300-fold less active than 3. These results are consistent with the putative interaction of this inhibitor 
class with the ATP-binding site of CDK2, which requires that the 6-substituent occupies a lipophilic 
pocket close to the ribose binding site, thereby orienting the purine to make the triplet of hydrogen 
bonds with the hinge region. 24 The low-micromolar potency of the 2-sulfanilyl derivative 13 likely 
reflects the contribution to binding arising through additional interactions between the 
arylsulfonamide group of 13 with the CDK2 surface adjacent to the ATP binding site on the C-
terminal lobe (termed the “specificity surface”), despite the absence of a 6-substituent. Perhaps not 
surprisingly, the guanine derivatives 15 and 16 were only weakly active, attributable to 
unfavourable interactions between the 6-oxo functionality and the ribose-binding pocket. These 
derivatives also exhibited the very poor aqueous solubility characteristic of many guanine 
derivatives. 
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Replacement of the 6-cyclohexylmethoxy group of 3 by smaller alkoxy substituents proved 
informative, and was broadly consistent with our earlier investigations with derivatives of 1. 31 In 
that study, 2-amino-6-methoxypurine (O6-methylguanine) demonstrated negligible activity (CDK2; 
IC50 > 100 µM), and the relatively poor chemical stability of this purine militated against preparing 
the corresponding 2-sulfanilyl analogue. The 6-ethoxypurine 30 exhibited high CDK2-inhibitory 
activity (IC50 = 26 nM), with an approximately three-fold increase in potency being observed for 
the n-propoxy- (31; IC50 = 8 nM) and iso-propoxy (32; IC50 = 10 nM) derivatives. Potency was 
improved further by increasing the size of the 6-alkoxy group, as demonstrated by the activity of the 
isomeric butoxy analogues 33 and 34 with IC50 values of 3 nM and 1 nM, respectively. The 
relationship between the bulk of the 6-alkoxy group and the CDK2-inhibitory activity generally 
parallels that previously observed for the corresponding 2-amino-6-alkoxypurines, albeit that the 
sulfanilylpurines 30-34 are several orders of magnitude more potent. For example, 34 (IC50 = 1 nM) 
is approximately 50,000-fold more potent than the corresponding 2-amino-6-sec-butoxypurine 
(CDK2; IC50 = 49 ± 7 µM), 
31 again corroborating the crucial binding contribution made by the 
arylsulfonamide function. A propargyloxy group at the purine O6-position conferred activity 
comparable to the ethoxy derivative (compare 35 and 30), in keeping with the trend reported 
previously for the 2-amino-6-alkoxypurine series. 31 
 
The introduction of an ethyl substituent at the purine 6-position (52) reduced CDK2-inhibitory 
activity some 10-fold compared with the 6-ethoxypurine (30), and very modest potency was also 
observed for the 6-ethynyl derivatives 41 and 42. Although 6-alkoxy and 6-alkyl groups differ with 
regard to both their electronic and steric character, as well as lipophilicity, the high potency of the 
6-triisopropylsilyethynylpurine (40; IC50 = 17 nM) shows that steric bulk, as well as electronic 
factors, is an important feature for binding in the ribose pocket of CDK2. The modest improvement 
in potency observed for the prop-1-ynyl (48) and phenylethynyl (49) derivatives compared with the 
parent 6-ethynylpurine 41, also suggests that the overall shape of the 6-substituent is an important 
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factor for occupancy of the ribose-binding pocket, supported by the activity of the 6-
cyclopropylpurine 55 (IC50 = 19 nM). These data also suggest that the oxygen atom of the 6-
alkoxypurines, which would act as a weak hydrogen bond acceptor, does not make a significant 
contribution to binding affinity. 
 
The potency of the 6-phenylpurine (70; IC50 = 24 nM) prompted further elaboration, with 
comparable activity residing in the 3-methoxyphenyl (71), 4-methoxyphenyl (72), and 6-(3-
phenylphenyl)purine (73) derivatives. By contrast, the piperonyl derivative (74) was some 20-fold 
less potent than 70, and the introduction of still larger groups was detrimental, as evident from the 
very weak CDK2-inhibitory activity of the dibenzofuran-1-yl (75) and thianthren-1-yl (76) 
analogues. The bulkier bicyclic and tricyclic heteroaromatic rings of these purines are presumably 
poorly accommodated within the ribose-binding pocket. It is of interest to note that the CDK2-
inhibitory activity of the 6-unsubstituted derivative 13 is equipotent with 75 and superior to that of 
76, implying that the 6-substituents of these purines make a negligible binding contribution. 
 
Table 1. Chemical structures and CDK2-inhibitory activity of purine derivatives 
 
No. Structure R
1
 R
2 
CDK2 Inhibition 
IC50 (µM)
a
 or Inhibition 
(%) at 100 µM 
1 A 
 
− 17 ± 2b 
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2 B 
 
H 0.97 ± 0.03 
3 B 
 
SO2NH2 0.005 ± 0.001 
8 A H −  (4 ± 3%)c 
12 B H H 61 ± 0.1 
13 B H SO2NH2 1.5 ± 0.1 
15 B OH (C=O)d H (34 ± 1%) 
16 B OH (C=O)d SO2NH2 (52 ± 4%) 
30 B OEt SO2NH2 0.026 ± 0.001 
31 B  SO2NH2 0.008 ± 0.002 
32 B 
 
SO2NH2 0.01 ± 0.001 
33 B 
 
SO2NH2 0.003 ± 0.0003 
34 B 
(rac) 
SO2NH2 0.001 ± 0.0005 
35 B 
 
SO2NH2 0.019 ± 0.001 
40 B  SO2NH2 0.017 ± 0.001 
41 B  H 21 ± 9 
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42 B  SO2NH2 0.83 ± 0.03 
48 B  H 6.4 ± 0.4 
49 B  H 8.9 ± 0.7 
52 B Et SO2NH2 0.22 ± 0.003 
55 B  SO2NH2 0.019 ± 0.001 
70 B Ph SO2NH2 0.024 ± 0.002 
71 B 
 
SO2NH2 0.039 ± 0.013 
72 B 
 
SO2NH2 0.052 ± 0.004 
73 B 
 
SO2NH2 0.044 ± 0.012 
74 B 
 
SO2NH2 0.58 ± 0.02 
75 B 
 
SO2NH2 1.4 ± 0.2 
76 B 
 
SO2NH2 6.7 ± 0.5 
aIC50 values were determined in accordance with previously described methods. 
20, 23 bData shown 
are the mean of at least two independent experiments ± standard deviation. c% inhibition values are 
in brackets. dThe oxo-tautomers predominate. 
Ph
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With a view to assessing selectivity for CDK2, selected purine derivatives were evaluated against a 
panel of CDKs (Table 2). As expected, removal of the 6-cyclohexylmethyl substituent of 3, which 
makes a number of interactions with the conserved ATP ribose binding site, to furnish 13 
compromised potency against all the CDKs evaluated, although the effect was less pronounced 
against CDK2.  
 
The 6-alkoxypurines 34 and 35 exhibited good selectivity for CDK2 over the closely related CDK1 
(80-fold and 50-fold, respectively), with 34 retaining selectivity over CDKs 4, 7 and 9 comparable 
with 3. A similar profile was observed for the 6-phenylpurine 70, which was some 30-fold selective 
for CDK2 over CDK1. By contrast, the 6-([1,1'-biphenyl]-3-yl)purine derivative 73 exhibited a very 
interesting CDK selectivity profile, proving some 2,000-fold selective for CDK2 over CDK1, whilst 
exhibiting only weak inhibitory activity against CDKs 4, 7, and 9. To the best of our knowledge this 
level of selectivity for CDK2 over CDK1 is unprecedented. 
 
Table 2. CDK selectivity and cellular activity for selected compounds 
 
Compd. R IC50 (µM) or % inhibition at 100 µM
a
 
  CDK1/B CDK2/A CDK4/D CDK7/H CDK9/T 
3 
 
 
0.25 ± 
0.05b 
0.005 ± 
0.001 
1.45 ± 
0.70 
4.40 ± 
0.90 
1.07 ± 
0.02 
13 
 
H 15.8 ± 1.2 1.5 ± 0.09 
(12 ± 
4%)c 
75 ± 3 38 ± 11 
34 
 
 
0.097 ± 
0.040 
0.0012 ± 
0.0005 
1.30 ± 
0.30 
2.8 ± 0.1 
0.57 ± 
0.05 
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35 
 
 
0.94 ± 0.1 
0.019 ± 
0.001 
8.8 ± 1.2 − − 
70 
 
Ph 
0.73 ± 
0.003  
0.024 ± 
0.002 
3.8 ± 1.4 6.8 ± 0.4 
0.57 ± 
0.04 
73 
 
86 ± 4 
0.044 ± 
0.012 
(26 ± 2%) (28 ± 6%) 25 ± 8 
aIC50 values were determined in accordance with previously described methods. 
20, 23 bData shown 
are the mean of at least two independent experiments ± standard deviation. c% inhibition values are 
in brackets. 
 
Modification of the core purine heterocycle of 1 and 3 afforded further interesting results (Table 3). 
A comparison of 2-amino-6-cyclohexylmethylpurine 1 with the alternative heterocycles 86, 87 and 
93 revealed that although these compounds exhibited comparable potency against CDK2, activity 
against other CDK family members was markedly attenuated. The very weak activity of the 
imidazopyrimidine derivatives 101 and 102 is not surprising given the absence of the requisite 
donor-acceptor-donor motif, and presumably reflects the combined influence arising from the 
absence of the N1 and N7 functions found in the corresponding purine derivatives 1 and 3. The 
modest CDK inhibition profile of imidazopyridine 83 indicates that removal of the N1 nitrogen is 
detrimental to CDK-inhibitory activity. However, with the exception of the imidazopyridine (83) 
and imidazopyrimidine (102) derivatives, modification of the core purine heterocycle of 3 was 
generally tolerated without a marked loss of CDK2-inhibitory activity. Thus, triazolopyrimidine 
(90) analogue is 2.5-fold more potent than 3, while pyrazolopyrimidine (91) and pyrrolopyrimidine 
(98) analogues proved only some 4-5-fold less potent than 3 against CDK2, and retained good 
selectivity over all other CDK family members examined. Notably, derivatives 91 and 98 were 
approximately 100-fold selective for CDK2 over CDK1. 
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Table 3. Chemical structures and CDK-inhibitory activity of other heterocyclic derivatives 
 
No. 
 
Structure 
 
R 
CDK Inhibitory Activity 
IC50 (µM)
a
 or Inhibition at 10 µM (%) 
   CDK1 CDK2 CDK4 CDK5 CDK7 CDK9 
1 
 
H 26 ± 4b 17 ± 2 (33 ± 9%)c 97 ± 3 (44 ± 6%) (42 ± 
11%) 
3 
 
0.25 ± 
0.05 
0.005 ± 
0.001 
1.5 ± 0.7 0.48 ± 
0.07 
4.4 ± 0.9 1.1 ± 0.2 
80 
 
H - 28.4 ± 0.8 - - - - 
83 
 
11 ± 2 0.29 ± 
0.01 
23 ± 1% (37 ± 2%) (37 ± 4%) (42 ± 5%) 
86 
 
H (21 ± 1%) 18 ± 1 (6.2 ± 
3.6%) 
(13 ± 1%) (13 ± 6%) (16 ± 8%) 
90 
 
0.75 ± 
0.06 
0.002 ± 
0.0001 
9.6 ± 0.5 3.3 ± 0.2 6.8 ± 0.7 0.75 ± 
0.03 
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Table 3 (continued). Chemical structures and CDK-inhibitory activity of other heterocyclic derivatives 
 
No. 
 
Structure 
 
R 
CDK Inhibitory Activity 
IC50 (µM)
a
 or Inhibition at 10 µM (%) 
   CDK1 CDK2 CDK4 CDK5 CDK7 CDK9 
 
87 
 
H (32 ± 1%) 16 ± 4 (0%) (14 ± 9%) (16 ± 7%) (16 ± 2%) 
91 
 
1.6 ± 0.2 0.018 ± 
0.001 
2.8 ± 0.3 5.9 ± 0.1 7.0 ± 0.3 4.6 ± 0.2 
93 
 
H (11 ± 3%) (41 ± 
10%)d 
(5.6 ± 
7.9%) 
(12 ± 1%) (5.1 ± 
5.5%) 
(0%) 
98 
 
2.7 ± 0.2 0.026 ± 
0.001 
1.9 ± 0.1 4.4 ± 0.6 4.1 ± 0.2 1.0 ± 0.2 
101 
 
H - (10 ± 6%) - - - - 
102 SO2NH2 - (36 ± 3%) - - - - 
a IC50 values were determined in accordance with previously described methods. 
20, 23 bData shown are the mean of at least two independent 
experiments ± standard deviation. c% inhibition values are in brackets. dValue determined at 100 µM.
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Cellular studies    
The ability of compounds to inhibit cellular proliferation was examined in a 5-day growth assay 
using five histologically distinct retinoblastoma protein (Rb)-proficient human tumour lines (A375 
melanoma, Calu-6 lung carcinoma, MDA-MB-231 breast adenocarcinoma, SJSA1 osteosarcoma 
and SKUT-1B uterine corpus leiomyosarcoma). Whilst compound 73 demonstrated appreciable 
nanomolar potency versus CDK2 in isolated kinase assays, the maximal concentration tested in 
cellular assays (30 µM) had no or limited effects on the growth of cells, thereby preventing the 
concentration that induced a 50% growth inhibitory (GI50) effect to be determined (data not shown). 
In contrast, compounds 91 and 98, which were only 2.4 and 1.7 fold more potent respectively in 
CDK2 kinase assays, dose-dependently inhibited the growth of each tumour cell line with GI50 
values ranging from 1 – 22 µM. The cellular activity of these compounds compared favourably to 
that of compound 3. 
 
Figure 1. Activity of compounds 3, 91 and 98 against tumour cell growth.
45
 Rb-proficient 
human tumour cell lines were incubated for 120h with compounds and cellular protein determined 
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by SRB assay. Dose-response curves and GI50 bar charts represent the mean ± SEM from 3 or 4 
independent experiments.  
 
Structure determination- Compounds within this series show greater activity towards CDK2 than 
CDK1, generally varying between 10 and 80-fold (Table 2).  However, 73 exhibits exceptional 
discrimination being a circa 2000-fold more potent inhibitor of CDK2.   In order to confirm the 
binding mode and to identify potential interactions that might explain the selectivity of 73 for 
CDK2 over CDK1, 73 and 3 were co-crystallised with CDK2-cyclin A and CDK1-cyclin B- cyclin-
dependent kinases regulatory subunit 2 (CKS2) respectively. The poor potency of 73 towards 
CDK1 appears to preclude determination of a CDK1-cyclin B-CKS2-73 co-complex structure, as 
despite repeated attempts we were unable to visualise the compound in the active site. The statistics 
for the datasets and for the crystallographic refinements are presented in Table 4. Compound 73 
emulates the interactions made by 3 within the CDK2 active site (Figure 2A). 24 Indeed, the purine 
and aniline rings of each inhibitor superimpose very well. The purine rings occupy the CDK2 ATP 
binding site and each makes a triplet of hydrogen bonds with the backbone carbonyl of Glu81 and 
the amide NH and carbonyl moieties of Leu83 within the hinge sequence (Figure 2A). The 
respective anilino rings project out of the CDK2 catalytic site so that the sulfonamide NH2 group 
and one of the oxygens in each make hydrogen bonds with the side chain and backbone nitrogen of 
Asp86, respectively.  
 
The structures of 73 and 3 differ in the substitution present at the purine C-6 position. The O6-
cyclohexylmethyl substituent of 3 occupies the ATP ribose binding pocket and is complementary in 
shape and forms favourable hydrophobic interactions with an apolar pocket created by the 
conformation of the CDK2 glycine-rich loop (residues 9-19). 24 This loop adopts an identical 
backbone structure when bound to 73, so that the purine-proximal phenyl ring emulates the position 
of the cyclohexylmethyl substitutent of 3. The distal phenyl ring substituted at the meta position can 
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then be comfortably accommodated as it twists towards the aniline moiety (Figure 2A).  In contrast, 
para substitutions of the purine-proximal phenyl ring exemplified by 72, 74, 75 and 76 (Table 1) 
would be directed out of the CDK2 active site towards the tip of the glycine-rich loop.  Smaller 
substitutions, for example a methoxy in 72 can be accommodated but larger ring systems as 
exemplified by 74 and 76 lead to considerable drops in potency suggesting they may sterically clash 
with the CDK2 structure in this region (Table 1). 
 
To probe further the binding mode of the series, CDK1-cyclin B-CKS2 was co-crystallised with 3 
(Figure 2B).  This structure shows that the purine backbone emulates the interactions made by this 
inhibitor within the CDK2 binding site and that the O6-cyclohexylmethyl substituent occupies the 
ribose binding pocket. As previously reported, 46 inhibitor binding within the ATP binding site is 
accompanied by minor remodelling of the CDK1-cyclin B into a conformation compatible with 
catalysis.  
 
All of the sidechains contacted by 73 in the co-complex with CDK2-cyclin A are conserved in 
CDK1, so that selectivity must derive from indirect readout of remote sequence differences.  One 
mechanism by which such differences can impact inhibitor binding is where they shape the 
conformational energy landscape, permitting conformations in one kinase that are precluded in 
another.  As described above, the glycine-rich loop makes a significant contribution to the catalytic 
cleft, shaping the binding site that accommodates the purine C-6 substituents. We note that the 
glycine-rich loop in the CDK2-cyclin A-73 structure adopts a conformation in which Tyr15 is 
folded into the active site, contacting residues of the C-helix (Figure 2C).  This position for the 
sidechain of Tyr15 is seen in a number of other CDK2-cyclin A-inhibitor complexes, suggesting 
that it reflects a preferred conformation of CDK2.  However, in available structures of apo CDK1-
cyclin B, and CDK1-cyclin bound to compound 23 46 or 3 (this paper), a comparable location for 
the side chain of Tyr15 has not been observed (Figure 2C). We speculate, therefore, that 73 binds 
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more tightly to CDK2 than to CDK1 because in doing so, it stabilises a glycine-rich loop 
conformation that is preferred in CDK2 but not in CDK1.  
 
Table 4. X-ray data collection and refinement statistics 
 
 CDK2-cyclin A-731 CDK1-cyclin B-
CKS2-31 
Data collection   
Space group P212121 P1 
Unit cell (Å) a=73.5, b=132.1, 
c=149.2 
a=65.0, b=67.8, 
c=85.1, α=103.9, 
β=90.9, γ=90.4  
 Resolution (Å) 
(highest resolution shell) 
66.03-2.97 
(3.13-2.97) 
65.76-2.06 
(2.10-2.06) 
Total observations  226,370 (7244) 169709 (8389) 
Unique 30,773 (1098) 84841 (4161) 
Rmerge
a 0.086 0.092 
Mean I/σ(I) 6.7 (1.6)  6.2 (1.2) 
Completeness % 100 (99.7) 97.3 (95.5) 
Refinement   
Total number of atoms 
protein 
other 
waters 
 
8,927 
64 
18 
 
20,449 
100 
291 
R (highest resolution 
shell) 
0.213 0.198 
Rfree (highest resolution 
shell) 
0.266 0.254 
Rmsd bonds (Å) 0.0122 0.0217 
Rmsd angles (o) 1.770 2.233 
 
1 The structures have been deposited in the PDB with accession codes 5LQE (CDK2-cyclin A-73) 
and 5LQF (CDK1-cyclin B-CKS2-3).  
 
 
Page 24 of 75
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Figure 2. Structures of CDK2-cyclin A-73 and CDK1-cyclin B-CKS2-3. (A)  Surface 
representation of CDK2 (ice blue) bound to cyclin A (coral) in complex with 73 (yellow).  The inset 
shows the interactions of 73 within the ATP site of CDK2-cyclin A. (B) Surface representation of 
F80 
K33 
Y15 
D145 
Q131 
73 
D86 
Q85 
H84 
L83 
F82 E81 
F80 
K33 
Y15 
D145 3 
D86 
M85 
S84 
L83 
F82 
E81 
Q132 
CDK2/A CDK1/B 
Gly-rich loop Gly-rich loop 
Tyr15 
Tyr15 
A 
B 
C 
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CDK1 (dark cyan) bound to cyclin B (pale crimson) and CKS2 (lemon) in complex with 3 (green).  
The inset shows the interactions of 3 within the ATP site of CDK1-cyclin B-CKS2. In (A) and (B) 
the protein backbone is rendered in ribbon representation and selected CDK2 and CDK1 residues 
are drawn respectively with carbon atoms coloured ice blue and dark cyan. The hydrogen bonds are 
shown as black dotted lines. (C) The structural conformations of the CDK2-cyclin A and CDK1-
cyclin B-CKS2 glycine-rich loops to illustrate the alternative poses of catalytic residue Tyr15. The 
left hand side panel compares CDK2-cyclin A in complex with 73 (ice blue) to other inhibitor 
bound CDK2-cyclin A complexes (PDB entries 4EOS (green), 3TNW (coral), and 3MY5 (lilac)). 
The right hand panel overlays CDK1-cyclin B-CKS2 bound to 3 (ice blue) with apo CDK1-cyclin 
B-CKS2 (PDB entry 4YC3, lilac) and CDK1-cyclin B-CKS2 in complex with compound 23 (PDB 
entry 5HQ0, green). The conformations of the loop when CDK1 is bound to 3 or Compound 23 
cannot be distinguished. Gly-rich loop, glycine-rich loop. 
 
Conclusions 
Novel 6-substituted 2-(4’-sulfamoylanilino)purines have been designed as competitive inhibitors 
acting at the ATP binding site of CDK2 with particular attention being given to abrogating activity 
against CDK1. A variety of substituents were explored, either attached directly to C-6 or via an 
oxygen link, in the context of their possible interaction with a lipophilic pocket close to the ATP 
ribose binding site. The relationship between the size of a 6-alkoxy group and CDK2-inhibitory 
activity was found to parallel that previously observed for the corresponding 2-amino-6-
alkoxypurines. In general, the new compounds were significantly less potent (typically 10-80×) 
against CDK1 than CDK2. Most impressive was 4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) 
benzenesulfonamide that was  ~ 2000-fold less active towards CDK1 (IC50 86 µM), whilst retaining 
high potency against CDK2 (0.044 µM). Compounds substituted with relatively large 
conformationally constrained groups, e.g. bicyclic and tricyclic aromatic systems, showed greatly 
reduced inhibitory activity, indicating poorly accommodation of these substituents in the lipophilic 
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binding site. Analogues of 6-cyclohexylmethoxy-2-(4’-sulfamoylanilino)purine, in which the purine 
ring was replaced by a triazolopyrimidine, pyrazolopyrimidine or pyrrolopyrimidine were only 
marginally less active against CDK2 than the parent purine. However, replacement with an 
imidazopyridine or imidazopyrimidine gave much less potent derivatives.  Co-crystal structures of 
inhibitors bound to CDK2 and CDK1 revealed that the binding mode of the purine-based inhibitor 
series is conserved. We show that inhibitor binding to CDK2 stabilises a glycine-rich loop 
conformation that shapes the ATP ribose binding pocket, resulting in effective inhibition of CDK2. 
We propose that this region of the active site might be the basis of the design of further inhibitors 
differentiating between CDK1 and CDK2. 
 
Experimental Section  
General Synthetic Procedures 
Chemicals and solvents were obtained from standard suppliers. Solvents were either dried by 
standard techniques or purchased as anhydrous. Reactions needing microwave irradiation were 
carried out in an InitiatorTM Sixty Biotage apparatus. Petrol refers to petroleum ether (bp 40–60 °C, 
reagent grade, Fisher Scientific). All reactions that required inert or dry atmosphere were carried out 
under a blanket of nitrogen, which was dried by passage through a column of phosphorus 
pentoxide. Glassware was dried in an oven prior to use. Column chromatography was carried out 
using 40-60 µm mesh silica in glass columns under medium pressure or with a Biotage SP4 flash 
purification system using KP-Si. Thin layer chromatography (TLC) was performed on 20 mm 
precoated plates of silica gel (Merck, silica gel 60F254); visualisation was achieved using 
ultraviolet light (254 nm). NMR spectra were recorded on a Bruker Spectrospin AC 300E (300 
MHz) NMR Spectrometer or Bruker BioSpin UltraShield Plus 500 MHz using deuterated solvent as 
a lock. IR spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR, and UV analysis was 
performed using a Hitachi U-2000 spectrophotometer. LC-MS analysis was carried out on a 
Micromass Platform instrument operating in positive and negative ion electrospray mode, 
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employing a 50 × 4.6 mm C18 column (Supelco Discovery or Waters Symmetry) and a 15 min 
gradient elution of 0.05% formic acid and methanol (10–90%). HRMS were measured using a 
Finnigan MAT 95 XP or a Finnigan MAT 900 XLT by the EPSRC National Mass Spectrometry 
Service Centre (Swansea). The purity of final compounds was assessed by reversed-phase HPLC; 
all tested compounds were >95% purity. HPLC instrument, Agilent 1200 equipped with a 
photodiode array detector (190-400 nm). Sample temperature, ambient; injection volume, 5 µL; 
flow rate, 1mL/min. 5% to 100% MeCN gradient over 9 min and an isocratic hold at 100% MeCN 
for 2.5 min, before returning to initial conditions. Mobile phase A = 0.1% ammonia in water or 
0.1% formic acid in water, mobile phase B = MeCN. Column: Waters XSELECT CSH C18, 3.5 
µm, 4.6 mm × 150 mm or Waters XTerra RP18, 5 µm, 4.6 mm × 150 mm. Column maintained at 
ambient temperature.  
General procedure A. To a stirred suspension of the appropriate haloheterocycle (1.0 mol. equiv.) 
and 4-aminobenzenesulfonamide (2.0 mol. equiv.) in TFE (25 mL/g of haloheterocycle) was added 
TFA (2.5 mL/g of haloheterocycle) dropwise. The resulting solution was heated under reflux for 12-
48 h under a nitrogen atmosphere. The solvent was removed in vacuo and the residue was 
redissolved in EtOAc (10-20 mL). The solution was washed with saturated aqueous sodium 
bicarbonate solution (3 × 10 mL), and the aqueous extracts were combined and washed with EtOAc 
(2 × 15 mL). The combined organic layers were dried (Na2SO4) and the solvent removed under 
reduced pressure to give a residue that was purified in the manner indicated. 
6-Chloro-2-fluoro-9H-purine (10).
 47
 To a stirred solution of HBF4 (48% aqueous, 120 mL) at 0 
ºC, was added 2-amino-6-chloropurine (9) (6.0 g, 35.0 mmol). Over 20 min, a solution of NaNO2 
(4.9 g, 70.0 mmol) in water (200 mL) was added dropwise, ensuring the temperature remained close 
to 0 ºC. The pale yellow solution was raised to room temperature and stirred for 18 h. The resulting 
solution was neutralised to pH 7 in an ice bath at 0 °C, by addition of Na2CO3 (6.00 g) in water (200 
mL). Solvents were removed in vacuo and the residual solid was redissolved in MeOH (100 mL) 
and adsorbed onto silica (250 mL). The crude material was purified by chromatography (silica; 10% 
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MeOH:DCM) to afford 10 as a white crystalline solid (4.52 g, 75%); mp 171-173 ºC (lit., 47 mp 174 
ºC); UV λmax (EtOH) 393 nm; IR (cm
-1) 2964, 2785, 1735, 1581; 1H NMR (500 MHz, DMSO-d6) δ 
8.60 (1H, s, H-8), 13.9 (1H, s, NH); LRMS (ES+) m/z 172.6 [M+H]+.  
2-Fluoro-9H-purine (11).
 48, 49 To a stirred suspension of 6-chloro-2-fluoropurine (10) (0.30 g, 1.74 
mmol) and palladium hydroxide on carbon (20% w/w, 0.30 g) in methanol (15 mL) was added 
ammonium formate (0.34 g, 5.35 mmol). The suspension was heated under reflux for 1h before 
filtering through a pad of Celite, eluting with methanol (20 mL). Removal of volatiles under 
reduced pressure afforded 11 as a white solid (240 mg, 100%); mp 219 °C (dec.) (lit., 48 
decomposed at 216 °C); 1H NMR (300 MHz, DMSO-d6) δ 8.60 (1H, s, H-8), 9.01 (1H, s, H-6), 13.9 
(1H, s, NH); LRMS (ES+) m/z 139.2 [M+H]+.  
Phenyl-(9H-purin-2-yl)amine (12). Prepared from aniline (0.182 mL, 2 mmol) and 2-fluoro-9H-
purine (11, 0.138 g, 1.0 mmol) in accordance with general procedure A. The reaction mixture was 
stirred under reflux for overnight. After removal of the solvent in vacuo the residue was dissolved 
in EtOAc (10-30 mL), washed with saturated aqueous NaHCO3 (3 × 30 mL) and dried (MgSO4). 
The crude material was purified by chromatography (silica; 0-20% MeOH:DCM), followed by 
recrystallization from DCM to afford 12 as an off-white solid (65 mg, 31%); Rf 0.20 (5% 
MeOH:DCM); mp 200-201 oC; UV λmax (EtOH) 328, 270, 239, 206 nm; IR (cm
-1) 3234, 3103, 
2804, 1624, 1602, 1539, 1402, 1292, 1217; 1H NMR (300 MHz, DMSO-d6) δ 6.91 (1H, t, J = 7.5 
Hz, H-4'), 7.28 (2H, t , J = 7.5 Hz, H-3' and H-5'), 7.83 (2H, d, J = 9.0 Hz, H-2' and H-6'), 8.82 (1H, 
s, H-6), 8.24 (1H, s, H-8), 9.53 (1H, s, NH), 12.9 (1H, s, NH); LRMS (ES+) m/z  212.0 [M+H]+; 
HRMS calcd for C11H10N5 [M+H]
+ 212.0931, found 212.0933. 
4-(9H-Purin-2-ylamino)benzenesulfonamide (13). Prepared following general procedure A 
from 2-fluoro-9H-purine (11, 0.10 g, 0.725 mmol). Recrystallization from MeOH:H2O gave 13 as a 
pale white solid (74 mg, 35%); Rf 0.40 (20% MeOH:DCM); mp > 320 
oC (dec); UV λmax (EtOH) 
287, 213 nm; IR (cm-1) 3223, 1585, 1481, 1307, 1251, 1148, 1091; 1H NMR (300 MHz, DMSO-d6) 
δ 7.17 (2H, s, SO2NH2), 7.73 (2H, d, J = 9.0 Hz, H-3' and H-5'); 7.99 (2H, d, J = 9.0 Hz, H-2' and 
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H-6'), 8.33 (1H, s, H-6), 8.00 (1H, s, H-8), 10.00 (1H, s, NH); LRMS (ES+) m/z 291.0 [M+H]+; 
HRMS calcd for C11H11N6O2S [M+H]
+  291.0659, found 291.0659. 
N
2
-Phenylguanine 2,2,2-trifluoroacetate (15). The title compound was prepared following 
general procedure A using 2-bromohypoxanthine (14, 1.00 g, 4.7 mmol), aniline (0.9 mL, 9.40 
mmol) to yield 15 as a white solid (1.17 g, 73%). The isolated compound was pure by analytical 
HPLC without the need for further purification; mp 229-231 ºC; UV λmax (EtOH) 273 nm;
 IR (cm-1) 
3332, 3128, 2943, 2756, 2555, 2387, 1678, 1572; 1H NMR (300 MHz, DMSO-d6) δ 7.07 (1H, t, J = 
7.5 Hz, H-4'), 7.36 (2H, dd, J = 7.5, 8.0 Hz, H-3' and H-5'), 7.62 (2 H, d, J = 8.0 Hz, H-2' and H-6'), 
7.94 (1H, s, H-8), 8.46 (1H, br s, NH), 9.00 (1H, br s, NH); 13C NMR (75 MHz, CDCl3) δ 113, 120, 
123, 129, 138, 139, 150, 152, 155; LRMS (ES+) m/z 228.3 [M+H]+; HRMS calcd for C11H10N5O 
[M+H]+ 228.0881, found 228.0880. 
6-Oxo-2-((4-sulfamoylphenyl)amino)-6,9-dihydro-1H-purine 2,2,2-trifluoroacetate (16). 
Synthesised in accordance with general procedure A from 2-bromohypoxanthine (14, 0.10 g, 0.47 
mmol) to yield 16 as an amorphous white solid (60 mg, 42%); mp > 300 ºC; UV λmax (EtOH) 275 
nm; IR (cm-1) 3348, 3113, 2990, 2877, 2792, 2333, 1672, 1575, 1365, 1153.; 1H NMR (300 MHz, 
DMSO-d6) δ 7.28 (2H, s, SO2NH2), 7.79 (4H, m, H-2', H-3', H-5' and H-6'), 8.31 (1H, s, H-8), 9.25 
(1H, br s, NH), 10.84 (1H, br s, NH); 13C NMR (75 MHz, CDCl3) δ 113, 120, 123, 127, 138, 139, 
150, 152, 156; LRMS (ES+) m/z 307.3 [M+H]+. 
1-(2-Amino-9H-purin-6-yl)-4-aza-1-azoniabicyclo[2.2.2]octane (17).
 34
 1,4-
Diazabicyclo[2.2.2]octane (9.90 g, 88.4 mmol) was added to a solution of 2-amino-6-chloropurine 9 
(5.00 g, 29.5 mmol) in DMSO (100 mL) over 1 h and the mixture was stirred at room temperature 
for 24 h. The resulting white precipitate was filtered and washed with diethyl ether. The solid was 
suspended in DCM (200 mL) and stirred for 1 h. After filtration and washing with DCM several 
times, 9 was obtained as a white solid, which was dried in vacuo (7.95 g, 96%) and used without 
further purification; mp 230 ºC (dec) (lit., 34 decomposed at 230 ºC); 1H NMR (300 MHz, D2O) δ 
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3.31 (6H, t, J = 7.5 Hz, (N(CH2)3), 4.07 (6H, t, J = 7.5 Hz, (N
+(CH2)3), 8.13 (1H, s, H-8); 
13C NMR 
(75 MHz, D2O) δ 38.7, 53.4, 116.0, 143.7, 151.3, 158.4. 
General procedure B. 2-Amino-6-chloropurine (9, 1.0 mol. equiv.) was added to a solution 
prepared from metallic sodium (5.0 mol. equiv.) dissolved in the appropriate alcohol (3.4 
mL/mmol).  The mixture was stirred at reflux until LCMS analysis indicated the absence of starting 
materials (3-24 h). After cooling, the reaction mixture was neutralised with glacial AcOH and the 
volatile material was removed in vacuo. Unless otherwise indicated, purification was achieved 
either by recrystallisation from H2O or by adding H2O to the reaction mixture and extracting the 
product into EtOAc (3 × 100 mL), followed by drying (MgSO4) and removal of the solvent in 
vacuo. 
General Procedure C. The appropriate alcohol (4.0 mol. equiv.) was added dropwise to a stirred 
suspension of NaH (3.0 mol. equiv.) in DMSO (2.5-3.0 mL/mmol) and the resulting mixture was 
stirred for 1-2 h.  To this was added DABCO-purine (17, 1.0 mol. equiv.) or the appropriate 
haloheterocycle (1.0 mol. equiv), and the mixture was stirred for 24 h with heating as specified. 
Water (20-200 mL) was added and the basic emulsion was neutralised with glacial acetic acid.  The 
aqueous phase was extracted with EtOAc (3 × 50-100 mL) and the organic layers were washed with 
saturated aqueous NaCl (100 mL).  The combined organic layers were dried (MgSO4) and 
concentrated in vacuo to yield the crude product, which was purified by chromatography on silica 
and/or recrystallisation from an appropriate solvent. 
General Procedure D. To a stirred solution of hydrofluoroboric acid (50%, aq., 20.0 mol. equiv.) 
cooled below -20 ºC, was added the appropriate 2-amino-6-alkoxypurine (1.0 mol. equiv.).  Whilst 
maintaining the temperature at –15 ºC, a solution of NaNO2 (2.0 mol. equiv.) in H2O (1-3 mL/mmol 
NaNO2) was added dropwise over 10 min. The mixture was stirred at room temperature for 3 h, 
neutralised at -15 ºC by the dropwise addition of 15% (w/v) aqueous Na2CO3 solution, and the 
precipitated solid was collected by filtration and washed with H2O. The residual solid was triturated 
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with EtOAc (3 × 100 mL) and filtered. The combined filtrates were concentrated under reduced 
pressure to furnish the product, which was purified as indicated. 
General procedure E. The appropriate 9-(tetrahydro-2H-pyran-2-yl)-9H-purine (1.0 mol. equiv.) 
was dissolved in 2-propanol (60 mL/g) and deionised water (20 mL/g). Trifluoroacetic acid (10.0 
mol. equiv.) was added, and the reaction mixture was stirred at 100 ºC for 2 h, cooled to room 
temperature, and the solution was adjusted to pH 8 by addition of conc. aqueous ammonia solution. 
The volume of solvent was reduced by 50% under reduced pressure; if a precipitate resulted, this 
was collected and washed with 2-propanol (2 × 10 mL). If precipitation was not observed following 
neutralisation, the reaction mixture was partitioned between EtOAc (20 mL) and saturated aqueous 
NaCl solution (20 mL) The organic layer was dried (Na2SO4), evaporated under reduced pressure, 
and the product was purified by chromatography as specified. 
General Procedure F. Tetrabutylammonium fluoride solution (1.0 M in THF, 1.5 mol. equiv.) was 
added dropwise to a stirred solution of the appropriate 6-triisopropylsilylethynylpurine (1.0 mol. 
equiv.) in anhydrous THF (10-20 mL), and the mixture was stirred for 5-15 min at ambient 
temperature under N2. Volatiles were evaporated under reduced pressure, and the residue was 
redissolved in EtOAc (100 mL/g), washed with saturated aqueous NaCl (100 mL/g), and the 
organic fraction was removed in vacuo. The product was purified as described. 
General Procedure G. An oxygen-free solution of the required boronic acid or potassium 
trifluoroborate salt (1.09 mmol), the appropriately 2-substituted 6-chloro-9-(tetrahydro-2H-pyran-2-
yl)-9H-purine (0.78 mmol), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (SPhos) (2.5 
mol%) and palladium acetate (1.0 mol%) in toluene (4 mL) was degassed by bubbling nitrogen 
through the solution in a sealed vial for 5 min. To the pale yellow solution was added K3PO4 (1.56 
mmol) and water (approx. 50 µL). The solution was again degassed for 15 min and subsequently 
heated to 100 ºC for 18 h. The black-brown suspension was filtered through Celite, eluting with 
MeOH (3 × 10 mL), and the product was isolated by chromatography as indicated. 
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2-Amino-6-ethoxypurine (18). 50, 51 Treatment of EtOH (100 mL) with Na (3.38 g, 147.5 mmol), 
followed by addition of 2-amino-6-chloropurine 9 (5.0 g, 29.5 mmol) according to general 
procedure B, afforded the crude product. Recrystallisation from H2O gave 18 as a white powder 
(4.75 g, 90%); Rf 0.26 (10% MeOH:DCM), mp 247 
oC (dec) (lit. 51 mp 230 oC (dec), lit. 50 mp 293 
oC (dec)); IR (cm-1) 3321, 2981, 2363, 2143, 1619, 1584, 1508, 1458, 1427, 1396, 1375, 1342, 
1285, 1223, 1161, 1118 cm-1, 1H NMR (300 MHz, DMSO-d6) δ 1.35 (3H, t, J = 7.1 Hz, CH3), 4.44 
(2H, q, J = 7.1 Hz, CH2), 6.21 (2H, s, NH2), 7.81 (1H, s, H-8); 
13C NMR (75 MHz, DMSO-d6) δ 
14.9, 61.6, 160.1; LRMS (ES+) m/z 180.3 [M+H]+; Anal. Found C 47.11 H 4.97 N 38.97; C7H9N5O 
requires C 46.92 H 5.06 N 39.09. 
2-Amino-6-n-propoxypurine (19).  50, 51 Treatment of 1-propanol (20 mL) with Na (0.68 g, 29.5 
mmol), followed by addition of 2-amino-6-chloropurine 9 (1.0 g, 5.9 mmol) according to general 
procedure B, gave the crude product.  Recrystallisation from H2O afforded 19 (1.06 g, 93%) as a 
yellow solid, Rf  0.21 (10% MeOH:DCM), mp 196-198 ºC (lit. 
51 mp 199-201 ºC, lit. 50 mp 208 ºC); 
IR (cm-1) 3484, 3389, 3318, 3203, 2965, 2935, 2882, 2522, 2361, 2338, 1578, 1507, 1449, 1398, 
1362, 1331, 1276, 1225, 1165, 1119; 1H NMR (300 MHz, DMSO-d6) δ 0.97 (3H, t, J = 7.4 Hz, 
CH3) 1.76 (2H, tq, J = 7.2, 7.2 Hz, CH3CH2CH2O), 4.34 (2H, t, J = 6.8 Hz, OCH2), 6.20 (2H, s, 
NH2), 7.82 (1H, s, H-8), 12.37 (1H, br s, NH); 
13C NMR (75 MHz, DMSO-d6) δ 10.7, 22.2, 67.3, 
138.5, 160.1, 160.3, 162.2; LRMS (ES+) m/z 194.17 [M+H]+; Anal. Found C 46.81 H 5.95 N 33.78; 
C8H11N5O.0.7 H2O requires C 46.69 H 6.07 N 34.03. 
2-Amino-6-isopropoxypurine (20). 31 Treatment of isopropanol (0.85 mL, 14.2 mmol) with NaH 
(0.26 mg, 10.7 mmol.) in DMSO (10 mL), followed by addition of 17 (1.0 g, 3.6 mmol) was 
performed according to general procedure C, to afford the crude product.  Purification by 
chromatography (silica; 5-10% MeOH:DCM) afforded 20 as a yellow oil.  Trituration of the oil 
with diethyl ether afforded 20 (0.38 g, 55%) as an off-white solid; Rf 0.28 (10% MeOH:DCM), mp 
205-207 ºC (lit. 31 mp 209-210 ºC); IR (cm-1) 3491, 3331, 3195, 2976, 2773, 1618, 1580, 1504, 
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1445, 1391, 1372, 1321, 1272, 1224, 1180, 1144; 1H NMR (300 MHz, DMSO-d6) δ 1.33 (6H, d, J 
= 6.2 Hz, 2 × CH3), 5.47 (1H, septet, J = 6.2 Hz, OCH), 6.17 (2H, s, NH2), 7.81 (1H, s, H-8), 12.39 
(1H, br s, NH); 13C NMR (75 MHz, DMSO-d6) δ 22.3, 68.2, 160.1; LRMS (ES
+) m/z 194.15 
[M+H]+; Anal. Found C 49.48 H 5.64 N 35.71; C8H11N5O.0.1 H2O requires C 49.27 H 5.79 N 
35.91 
2-Amino-6-(2-methyl-1-propoxy)purine (21). 31 2-Methyl-1-propanol (1.31 mL, 14.2 mmol) was 
added to NaH (0.25 mg, 10.7 mmol) in DMSO (10 mL), followed by addition of 17 (1.0 g, 3.6 
mmol) according to general procedure C, to afford the crude product.  Trituration of the residual 
yellow oil with petrol furnished a cream solid.  Purification by chromatography (silica; 5-10% 
MeOH:DCM) gave 21 (0.42 g, 57%) as pale yellow crystals; Rf 0.41 (10% MeOH/DCM), mp 180-
182 ºC (lit. 31 mp 89-92 ºC); IR (cm-1) 3512, 3473, 3359, 2958, 2875, 1620, 1575, 1507, 1451, 
1386, 1363, 1332, 1272, 1223, 1159, 1121; 1H NMR (300 MHz, DMSO-d6) δ 0.98 (6H, d, J = 6.7 
Hz, 2 × CH3), 2.07 (1H, septet, J = 6.7 Hz, OCH2CH), 4.17 (2H, d, J = 6.8 Hz, OCH2), 6.21 (2H, s, 
NH2), 7.82 (1H, s, H-8); 
13C NMR (75 MHz, DMSO-d6) δ 19.4, 27.8, 71.9, 160.1, 162.2; LRMS 
(ES-) m/z 206.81 [M-H]-. 
2-Amino-6-(1-methylpropoxy)purine (22). 
31 Treatment of 2-butanol (20 mL) with Na (0.68 g, 
29.5 mmol), followed by addition of 2-amino-6-chloropurine 9 (1.0 g, 5.9 mmol) was performed 
according to general procedure B, to give a pale yellow solid.  H2O was added and the product 
was extracted into EtOAc (3 × 100 mL), dried (MgSO4) and the solvent removed in vacuo to yield 
22 (0.90 g, 74%) as off-white crystals, Rf 0.3 (10% MeOH:DCM); mp 77 ºC (dec) (lit. 
31 mp 88-90 
ºC); IR (cm-1) 3322, 3190, 2971, 2936, 2876, 2772, 1616, 1575, 1504, 1451, 1393, 1375, 1326, 
1273, 1222; 1H NMR (300 MHz, DMSO-d6) δ 0.91 (3H, t, J = 7.4 Hz, CH3CH2CHCH3), 1.29 (3H, 
d, J = 6.2 Hz, CH3CH2CHCH3), 1.57-1.79 (2H, m, CH3CH2CHCH3), 5.27-5.38 (1H, m, 
CH3CH2CHCH3), 6.19 (2H, s, NH2), 7.79 (1H, s, H-8); 
13C NMR (75 MHz, DMSO-d6) δ 10.0, 
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19.8, 28.9, 72.7, 137.7, 160.1; LRMS (ES-) m/z 206.08 [M-H]-; Anal. Found C 51.52 H 6.43 N 
32.64; C9H13N5O.0.25 H2O requires C 51.05 H 6.43 N 33.08. 
2-Amino-6-(prop-2-ynyloxy)purine (23). 51 Treatment of propargyl alcohol (0.83 mL, 14.2 mmol) 
with NaH (0.25 mg, 10.7 mmol) in DMSO (10 mL), followed by addition of 17 (1.0 g, 3.6 mmol) 
was performed according to general procedure C, affording the product 23 (0.54 g, 80%) as a 
beige solid, Rf 0.26 (10% MeOH:DCM); mp 181 ºC (dec) (lit. 
51 mp 230 ºC (dec)); IR (cm-1) 3319, 
3190, 2777, 2126, 1651, 1621, 1589, 1510, 1460, 1438, 1400, 1339, 1277, 1221, 1184, 1142; 1H 
NMR (300 MHz, DMSO-d6) δ 3.58 (1H, t, J = 2.4 Hz, OCH2CCH), 5.10 (2H, d, J = 2.4 Hz, 
OCH2CCH), 6.35 (2H, s, NH2), 7.85 (1H, s, H-8); 
13C NMR (75 MHz, DMSO-d6) δ 53.0, 78.0, 
79.6, 113.7, 138.5, 155.7, 159.1, 159.9; LRMS (ES+) m/z 190.00 [M+H]+. 
2-Fluoro-6-ethoxypurine (24). Prepared following general procedure D from 18 (1.0 g, 5.6 
mmol) to give 24 as a white solid (0.22 g, 22%); Rf 0.39 (10% MeOH/DCM); mp 225-227 ºC; IR 
(cm-1) 3117, 2997, 2740, 2669, 2506, 2363, 2339, 1836, 1760, 1605, 1487, 1425, 1373, 1343, 1281, 
1219, 1151, 1111, 1038, 1007; 1H NMR (300 MHz, DMSO-d6) δ 1.41 (3H, t, J = 7.1 Hz, CH3), 
4.57 (2H, q, J = 7.1 Hz, CH2), 8.39 (1H, s, H-8), 13.55 (1H, br s, NH); 
13C NMR (75 MHz, DMSO-
d6) δ 14.6 (CH3), 64.0 (CH2), 144.0 (C
8); LRMS (ES+) m/z 183.1 [M+H]+; Anal. Found C 44.80 H 
3.67 N 29.48; C7H7N4OF.0.3 H2O requires C 44.83 H 4.08 N 29.87. 
2-Fluoro-6-n-propoxypurine (25). Synthesised in accordance with general procedure D from 19 
(1.0 g, 5.2 mmol) to yield 25 (0.58 g, 57%) as a white solid; Rf  0.18 (70% EtOAc:petrol); mp 197-
199 ºC; IR (cm-1) 3105, 2973, 2944, 2886, 2741, 2680, 2523, 2362, 2338, 1772, 1607, 1422, 1368, 
1347, 1269, 1213, 1149, 1038; 1H NMR (300 MHz, DMSO-d6) δ 1.00 (3H, t, J = 7.4 Hz, CH3) 1.82 
(2H, tq, J = 7.1, 7.1 Hz, CH3CH2CH2O), 4.47 (2H, t, J = 6.7 Hz, CH3CH2CH2O), 8.39 (1H, s, H-8), 
13.55 (1H, br s, NH); 13C NMR (75 MHz, DMSO-d6) δ 10.5 (CH3), 22.0 (CH3CH2CH2O), 69.4 
(O6CH2), 144.0 (Ar-C), 156.0 (C
8), 158.8 (Ar-C); LRMS (ES+) m/z 154.0 [M-C3H7]
+; HRMS calcd 
for C8H9FN4O [M
+] 196.0760, found 196.0757. 
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2-Fluoro-6-isopropoxypurine (26). Synthesised by general prodecure D from 20 (0.30 g, 1.6 
mmol) to yield 26 as a white solid (0.16 g, 53%); Rf 0.22 (70% EtOAc:petrol); mp 184 ºC (dec); IR 
(cm-1) 2990, 2536, 1605, 1472, 1424, 1371, 1275, 1034, 1017; 1H NMR (300 MHz, DMSO-d6) δ 
1.40 (6H, d, J = 6.2 Hz, 2 × CH3), 5.49 (1H, septet, J = 6.2 Hz, OCH), 8.37 (1H, s, H-8), 13.52 
(1H, br s, NH); 13C NMR (75 MHz, DMSO-d6) δ 22.0 (CH3), 71.5 (O
6CH), 162.2 (C8); LRMS 
(ES+) m/z 154.0 [M-C3H7]
+; HRMS calcd for C8H9FN4O [M
+] 196.0760, found 196.0760. 
2-Fluoro-6-(2-methyl-1-propoxy)purine (27). From 21 (0.40 g, 1.9 mmol) in accordance with 
general procedure D to yield 27 (0.25 g, 62%) as a white solid; Rf 0.25 (70% EtOAc:petrol); mp 
202-204 ºC; IR (cm-1) 3130, 3059, 2968, 2937, 2884, 2804, 2693, 2528, 1760, 1700, 1603, 1476, 
1451, 1418, 1364, 1341, 1267, 1211, 1140, 1113, 1040; 1H NMR (300 MHz, DMSO-d6) δ 1.01 
(6H, d, J = 6.7 Hz, 2 × CH3), 2.13 (1H, septet, J = 6.7 Hz, OCH2CH), 4.30 (2H, d, J = 6.7 Hz, 
OCH2), 8.40 (1H, s, H-8), 13.55 (1H, br s, NH); 
13C NMR (75 MHz, DMSO-d6) δ 19.2 (CH3), 27.7 
(O6CH2CH), 73.7 (O
6CH2); LRMS (ES
+) m/z 154.0 [M-C3H7]
+; HRMS calcd for C9H11FN4O [M
+] 
210.0917, found 210.0922. 
2-Fluoro-6-(1-methylpropoxy)purine (28). Prepared according to general procedure D from 22 
(0.66 g, 3.2 mmol) as a white solid (0.29 g, 43%); Rf 0.21 (70% EtOAc:petrol); mp 187-189 ºC; IR 
(cm-1) 2975, 2940, 1604, 1468, 1421, 1372, 1344, 1277, 1211, 1148, 1038; 1H NMR (300 MHz, 
DMSO-d6) δ 0.93 (3H, t, J = 7.4 Hz, CH3CH2CHCH3), 1.36 (3H, d, J = 6.2 Hz, CH3CH2CHCH3), 
1.66-1.83 (2H, m, CH3CH2CHCH3), 5.29-5.37 (1H, m, CH3CH2CHCH3), 8.37 (1H, s, H-8), 13.55 
(1H, s, NH); 13C NMR (75 MHz, DMSO-d6) δ 9.8 (CH3CH2CHCH3), 19.5 (CH3CH2CHCH3), 28.6 
(CH3CH2CHCH3), 75.9 (CH3CH2CHCH3), 158.8 (C
8); LRMS (ES-) m/z 209.1 [M-H]-; Anal. Found 
C 51.71 H 5.27 N 26.33; C9H11N4OF requires C 51.42 H 5.27 N 26.65. 
2-Fluoro-6-(prop-2-ynyloxy)purine (29). Synthesised from 23 (0.28 g, 1.5 mmol) in accordance 
with general procedure D as a pale yellow solid (77 mg, 27%); Rf 0.18 (70% EtOAc:petrol); mp 
201 ºC (dec); IR (cm-1) 3261, 3123, 2970, 2864, 2803, 2363, 2336, 2140, 1651, 1607, 1460, 1379, 
1341, 1275, 1217, 1142, 1107, 1048; 1H NMR (300 MHz, DMSO-d6) δ 3.70 (1H, t, J = 2.4 Hz, 
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OCH2CCH), 5.23 (2H, d, J = 2.2 Hz, OCH2CCH), 8.45 (1H, s, H-8); 
13C NMR (75 MHz, DMSO-
d6) δ 55.4 (O
6CH2CCH), 78.5 (O
6
CH2CCH), 79.1 (O
6CH2CCH), 162.2 (C
8); LRMS (ES+) m/z 
192.0 [M+]; HRMS calcd for C8H5FN4O [M
+] 192.0447, found 192.0448. 
2-Sulfanilyl-6-ethoxypurine (30). Prepared from 24 (0.20 g, 1.1 mmol) following general 
procedure A. Purification by chromatography (silica; 5-20% MeOH:DCM) afforded 30 (39 mg, 
11%) as an off-white solid; Rf 0.20 (10% MeOH:DCM); mp 265 ºC (dec); UV λmax (EtOH) 257, 
241 nm; IR (cm-1) 3473, 3317, 3223, 2984, 2787, 2363, 2338, 1628, 1578, 1540, 1499, 1442, 1376, 
1312, 1254, 1142, 1013; 1H NMR (300 MHz, DMSO-d6) δ 1.43 (3H, t, J = 7.1 Hz, CH3), 4.59 (2H, 
q, J = 7.1 Hz, CH2), 7.16 (2H, s, NH2), 7.71 (2H, d, J = 8.9 Hz, H-3' and H-5'), 7.97 (2H, d, J = 8.9 
Hz, H-2' and H-6'), 8.08 (1H, s, H-8), 9.76 (1H, s, NH), 12.69 (1H, s, NH); 13C NMR (75 MHz, 
DMSO-d6) δ 14.9 (CH3), 62.6 (CH2), 117.6 (Ar-C), 126.8 (Ar-C), 155.1 (C
8); LRMS (ES+) m/z 
335.0 [M+H]+; HRMS calcd for C13H14N6O3S [M
+] 334.0848, found 334.0835. 
2-Sulfanilyl-6-propoxypurine (31). Prepared from 25 (0.25 g, 1.3 mmol) according to general 
procedure A. Purification by chromatography (silica; 50-100% EtOAc:petrol followed by 0-10% 
MeOH:DCM), afforded 31 (0.25 g, 56%) as a beige solid; Rf 0.10 (70% EtOAc:petrol); mp 207 ºC 
(dec); UV λmax (EtOH) 310 nm; IR (cm
-1) 3251, 3115, 2971, 2934, 2878, 2361, 2340, 1700, 1596, 
1580, 1528, 1498, 1453, 1389, 1321, 1306, 1243, 1146, 1094; 1H NMR (300 MHz, DMSO-d6) δ 
1.03 (3H, t, J = 7.4 Hz, CH3) 1.85 (2H, tq, J = 6.9, 6.9 Hz, CH3CH2CH2O), 4.50 (2H, t, J = 6.8 Hz, 
CH3CH2CH2O), 7.17 (2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2' and H-6'), 7.97 (2H, d, J = 8.8 Hz, 
H-3' and H-5'), 8.09 (1H, s, H-8), 9.77 (1H, s, NH), 12.96 (1H, br s, NH); 13C NMR (75 MHz, 
DMSO-d6) δ 10.7 (CH3), 22.2 (CH3CH2CH2O), 68.2 (O
6CH2), 117.6 (CHCNH), 126.8 
(CHCSO2NH2), 135.7 (Ar-CNH), 144.6 (CSO2NH2), 155.1 (C
8); LRMS (ES+) m/z 349.8 [M+H]+; 
HRMS calcd for C14H16N6O3S [M
+] 348.1005, found 348.0994; Anal. Found C 45.41 H 4.75 N 
22.40; C14H16N6O3S.0.3 CF3CO2H requires C 45.83 H 4.29 N 21.97. 
2-Sulfanilyl-6-isopropoxypurine (32). Synthesised in accordance with general procedure A from 
26 (0.07 g, 0.4 mmol). Purification by chromatography (silica; 50-100% EtOAc:petrol followed by 
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0-10% MeOH:DCM), afforded 32 (38 mg, 31%) as a beige solid; Rf 0.03 (70% EtOAc:petrol); mp 
177 ºC (dec); UV λmax (EtOH) 307 nm; IR (cm
-1) 3472, 3312, 3210, 3117, 2982, 2793, 2691, 2643, 
2362, 2342, 1715, 1685, 1617, 1597, 1578, 1538, 1500, 1440, 1381, 1306, 1255, 1140, 1117, 1096; 
1H NMR (300 MHz, DMSO-d6) δ 1.42 (6H, d, J = 6.2 Hz, 2 × CH3), 5.59 (1H, septet, J = 6.2 Hz, 
OCH), 7.16 (2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2' and H-6'), 7.96 (2H, d, J = 8.8 Hz, 2 × H-3' 
and H-5'), 8.07 (1H, s, H-8), 9.74 (1H, s, NH), 12.91 (1H, br s, NH); 13C NMR (75 MHz, DMSO-
d6) δ 21.9 (CH3), 69.0 (O
6CH), 117.1 (CHCNH), 126.5 (CHCSO2NH2), 135.2 (Ar-CNH), 144.3 
(CSO2NH2), 154.7 (C
8); LRMS (ES+) m/z 349.8 [M+H]+; HRMS calcd for C14H16N6O3S [M
+] 
348.1005, found 348.1007. 
2-Sulfanilyl-6-(2-methyl-1-propoxy)purine (33). Prepared following general procedure A from 
27 (0.12 g, 0.6 mmol). Purification by chromatography (silica, 50-100% EtOAc:petrol followed by 
0-10% MeOH:DCM), afforded 33 (0.11 g, 53%) as a light brown solid; Rf 0.21 (70% 
EtOAc:petrol); mp 133 ºC (dec); UV λmax (EtOH) 308 nm; IR (cm
-1) 3285, 3108, 2962, 2360, 2337, 
1595, 1576, 1543, 1499, 1438, 1396, 1321, 1249, 1221, 1144, 1096, 1016; 1H NMR (300 MHz, 
DMSO-d6) δ 1.03 (6H, d, J = 6.7 Hz, 2 × CH3), 2.16 (1H, septet, J = 6.7 Hz, OCH2CH), 4.33 (2H, 
d, J = 6.8 Hz, OCH2CH), 7.17 (2H, s, NH2), 7.71 (2H, d, J = 8.9 Hz, H-2' and H-6'), 7.97 (2H, d, J 
= 8.9 Hz, H-3' and H-5'), 8.09 (1H, s, H-8), 9.77 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6) δ 
19.4 (CH3), 27.9 (O
6CH2CH), 72.7 (O
6CH2), 117.6 (CHCNH), 126.8 (CHCSO2NH2), 135.7 (Ar-
CNH), 144.6 (CSO2NH2), 155.1 (C
8); LRMS (ES+) m/z 363.8 [M+H]+; HRMS calcd for 
C15H18N6O3S [M
+] 362.1161, found 362.1145.  
(R/S)-6-(1-Methylpropoxy)-2-sulfanilylpurine (34). Synthesised from 28 (0.1 g, 0.5 mmol) 
following general procedure A. Purification by chromatography (silica; 50-100% EtOAc:petrol 
followed by 0-10% MeOH:DCM), afforded 34 (41 mg, 24%) as a light brown solid; Rf 0.10 (70% 
EtOAc:petrol); mp 162 ºC (dec); UV (EtOH) λmax 308 nm; IR (cm
-1) 3649, 3317, 3219, 3106, 2972, 
2938, 2874, 2363, 2340, 1701, 1596, 1579, 1528, 1498, 1453, 1389, 1306, 1243, 1145, 1094; 1H 
NMR (300 MHz, DMSO-d6) δ 0.97 (3H, t, J = 7.4 Hz, CH3CH2CHCH3), 1.39 (3H, d, J = 6.2 Hz, 
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CH3CH2CHCH3), 1.68-1.87 (2H, m, CH3CH2CHCH3), 5.40-5.46 (1H, m, CH3CH2CHCH3), 7.17 
(2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2' and H-6'), 7.96 (2H, d, J = 8.9 Hz, H-3' and H-5'), 8.13 
(1H, s, H-8), 9.76 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6) δ 10.0 (CH3CH2CHCH3), 19.7 
(CH3CH2CHCH3), 28.8 (CH3CH2CHCH3), 74.2 (CH3CH2CHCH3), 117.6 (CHCNH), 126.8 
(CHCSO2NH2), 135.8 (Ar-CNH), 144.6 (CSO2NH2), 155.2 (C
8); LRMS (ES+) m/z 363.8 [M+H]+; 
HRMS calcd for C15H18N6O3S [M
+] 362.1161, found 362.1166; Anal. Found C 48.32 H 5.15 N 
22.08; C15H18N6O3S.0.2 CF3CO2H requires C 48.02 H 4.76 N 21.82. 
2- Sulfanilyl-6-(prop-2-ynyloxy)purine (35). Synthesised in accordance with general procedure 
A from 29 (0.045 g, 0.2 mmol). Purification by chromatography (silica; 50-100% EtOAc:petrol 
followed by 0-10% MeOH:DCM), yielded 35 (27 mg, 34%) as a beige solid; Rf 0.1 (70% 
EtOAc:petrol); mp 161 ºC (dec); UV (EtOH) λmax 307 nm; IR (cm
-1) 3370, 3245, 2971, 2795, 2361, 
2340, 1715, 1699, 1619, 1585, 1575, 1540, 1499, 1472, 1454, 1443, 1396, 1321, 1307, 1271, 1143, 
1095; 1H NMR (300 MHz, DMSO-d6) δ 3.68 (1H, t, J = 2.3 Hz, OCH2CCH), 5.24 (2H, d, J = 2.3 
Hz, OCH2CCH), 7.18 (2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2' and H-6'), 7.98 (2H, d, J = 8.8 Hz, 
H-3' and H-5'), 8.13 (1H, s, H-8), 9.87 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6) δ 53.6 
(O6CH2CCH), 78.0 (O
6
CH2CCH), 79.1 (O
6CH2CCH), 115.1 (Ar-C), 117.5 (CHCNH), 126.5 
(CHCSO2NH2), 135.5 (Ar-CNH), 139.9 (C
2NH),  143.9 (CSO2NH2), 154.3 (C
8), 158.6 (Ar-C); 
LRMS (ES+) m/z 345.8 [M+H]+ ; HRMS calcd for C14H12N6O3S [M
+] 344.0692, found 344.0700. 
6-Chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (36). 3,4-Dihydropyran (60 µL, 0.58 
mmol) was added dropwise over 10 min to a vigorously stirred solution of 10 (0.10 g, 0.58 mmol) 
and (rac)-camphorsulfonic acid (5 mg, 0.02 mmol) in EtOAc (50 mL) at 65 ºC. The temperature 
was maintained at 65 ºC for 18 h. The resulting bright yellow solution was neutralised to pH 7 by 
careful addition of aqueous NH3 solution, until a cloudy suspension persisted. The crude mixture 
was washed with brine (2 × 30 mL) and the aqueous phase was re-extracted with EtOAc (2 × 30 
mL). The combined organic extracts were dried (Na2SO4) and purified by chromatography (silica; 
30% EtOAc:petrol) to afford 36 as a pale yellow oil which became a white waxy solid on 
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refrigeration (110 mg, 75%); mp 92-94 °C; UV λmax (EtOH) 269 nm; IR (cm
-1) 3132, 2955, 2876, 
1574; 1H NMR (500 MHz, DMSO-d6) δ 1.57-1.64 (2H, m, CH2), 1.70-1.80 (1H, m, CH), 1.94-2.02 
(2H, m, CH2), 2.23-2.32 (1H, m, CH), 3.70-3.77 (1H, m, CH), 4.00-4.06 (1H, m, CH), 5.71 (1H, dd, 
J = 2.3, 10.9 Hz, NCH), 8.92 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) δ 22.0 (N
9-
CHCH2CH2), 24.3 (N
9-CHOCH2CH2), 29.6 (N
9-CHCH2CH2), 67.7 (N
9-CHOCH2CH2), 81.7 (N
9-
CH), 130.1 (d, JCF = 4.8 Hz, Ar-C), 146.4 (d, JCF = 2.8 Hz, Ar-C), 150.6 (d, JCF = 18.5 Hz, Ar-C), 
153.2 (d, JCF = 17.6 Hz, Ar-C), 156.2 (d, JCF = 213.7 Hz, Ar-C
2); LRMS (ES+) m/z 257.2 [M+H]+. 
2-Fluoro-9-(tetrahydro-2H-pyran-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purine (37). An 
oxygen-free solution of 36 (0.050 g, 1.95 mmol), bis(triphenylphosphine)palladium (II) chloride (41 
mg, 3.0 mol%) and copper iodide (7 mg, 2.0 mol%) in THF (10 mL) was degassed by bubbling 
nitrogen through the solution in a sealed vial for 5 min. Triisopropylsilylacetylene (0.50 mL, 2.2 
mmol) and triethylamine (0.70 mL, 4.9 mmol) were added to the mixture, which was again 
degassed for 15 min. After stirring at room temperature for 18 h, the black-brown suspension was 
filtered through Celite, eluting with MeOH (3 × 20 mL). Purification by chromatography (silica; 
10% EtOAc:petrol) furnished 37 as a viscous yellow oil (78 mg, 99%); Rf 0.30 (10% 
EtOAc:petrol); UV λmax (EtOH) 303 nm; IR (cm
-1) 3433, 2946, 2866, 2706, 2361, 1703; 1H NMR 
(500 MHz, DMSO-d6) δ 1.12-1.25 (21H, m, Si(CH(CH3)2)3), 1.56-1.63 (2H, m, CH2), 1.71-1.80 
(1H, m, CH), 1.94-2.03 (2H, m, CH2), 2.20-2.30 (1H, m, CH), 3.70-3.78 (1H, m, CH), 4.01-4.07 
(1H, m, CH), 5.70 (1H, dd, J = 2.2, 10.8 Hz, NCH), 8.89 (1H, s, H-8); 13C NMR (125 MHz, 
DMSO-d6) δ 10.5 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 22.0 (N
9-CHCH2CH2), 24.4 (N
9-
CHOCH2CH2), 29.7 (N
9-CHCH2CH2), 67.7 (N
9-CHOCH2CH2), 81.4 (N
9-CH), 100.2 (C≡C), 102.8 
(C≡C), 133.9 (d, JCF = 4.6 Hz, Ar-C), 140.8 (d, JCF = 17.9 Hz, Ar-C), 146.6 (d, JCF = 2.8 Hz, Ar-C), 
153.8 (d, JCF = 17.8 Hz, Ar-C), 157.4 (d, JCF = 210.6 Hz, Ar-C
2); HRMS calcd for C21H32FN4OSi 
[M+H]+ 403.2324, found 403.2324. 
2-Fluoro-6-((triisopropylsilyl)ethynyl)-9H-purine (38). The title compound was prepared 
according to general procedure E from 37 (0.29 g, 0.72 mmol). Purification by chromatography 
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(silica; 30% EtOAc:petrol) gave 38 as a pale yellow oil (22 mg, 96%); Rf 0.25 (30% EtOAc:petrol); 
UV λmax (EtOH) 302 nm; IR (cm
-1) 2945, 2866, 2361, 2000, 1584; 1H NMR (500 MHz, DMSO-d6) 
δ 1.12-1.21 (21H, m, Si(CH(CH3)2)3), 8.68 (1H, s, H-8), 13.89 (1H, br, NH);
 13C NMR (125 MHz, 
CDCl3) δ 11.1 (Si(CH(CH3)2)3), 18.5 (Si(CH(CH3)2)3), 99.5 (C≡C), 106.1 (C≡C), 131.2 (m, Ar-C), 
141.6 (m, Ar-C), 145.3 (m, Ar-C), 156.6 (m, Ar-C), 158.6 (d, JCF = 217.4 Hz, Ar-C
2); HRMS calcd 
for C16H24FN4Si [M+H]
+ 319.1749, found 319.1752. 
6-(2-(Triisopropylsilyl)ethynyl)-N-phenyl-9H-purin-2-amine (39). Prepared in accordance with 
general procedure A from 38 (0.455 g, 1.43 mmol). Purified by chromatography (silica; 5% 
MeOH:DCM) to give the title compound as a yellow gum (0.39 g, 1.00 mmol, 70%); Rf 0.39 (5% 
MeOH:DCM); UV λmax (EtOH) 276 nm; IR (cm
-1) 3389, 2361, 2021; 1H NMR (500 MHz, CDCl3) 
δ 1.09-1.22 (21H, m, Si(CH(CH3)2)3), 7.00-7.04 (1H, m, H-4'), 7.22 (1H, s, NH), 7.29 (2H, dd, J = 
7.7, 8.1 Hz, H-3' and H-5'), 7.46 (1H, s, H-8), 7.52 (2H, dd, J = 1.7, 7.7 Hz, H-2' and H-6'), 10.42 
(1H, s, NH); 13C NMR (125 MHz, CDCl3) δ 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 100.8 
(C≡C), 101.8 (C≡C), 120.7 (Ar-C), 123.7 (Ar-C), 129.4 (Ar-C), 139.2 (Ar-C), 141.0 (Ar-C), 142.6 
(Ar-C), 153.4 (Ar-C), 156.5 (Ar-C); LRMS (ES+) m/z 392.0 [M+H]+. 
4-(6-((Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)benzenesulfonamide (40). Following 
general procedure A employing 38 (0.156 g, 0.49 mmol). Purification by reversed phase column 
chromatography (C18 silica; 25% to 95% MeCN/water + 0.1% HCOOH), afforded 40 as a yellow 
solid (70 mg, 30%); mp 163-165 ºC; UV λmax (EtOH) 361 nm; IR (cm
-1) 3327, 2944, 2867, 1569, 
1531, 1368, 1149; 1H NMR (500 MHz, DMSO-d6) δ 1.15 (21H, m, Si(CH(CH3)2)3), 7.17 (2H, s, 
SO2NH2), 7.70 (2H, d, J = 9.0 Hz, H-2' and H-6'), 7.95 (2H, d, J = 9.0 Hz, H-3' and H-5'), 8.33 (1H, 
s, H-8); 13C NMR (125 MHz, DMSO-d6) δ 10.6, 18.4, 90.6, 98.4, 117.1, 123.4, 126.5, 135.6, 144.0, 
155.5, 165.0, 166.3, 166.5; 291.0, 286.5, 215.5; LRMS (ES+)  m/z 471.4 [M+H]+; HRMS calcd for 
C22H30N6O2SSi [M+H]
+ 471.1987, found 471.1942. 
6-Ethynyl-N-phenyl-9H-purin-2-amine (41). Treatment of 39 (0.330 g, 0.84 mmol) according to 
general procedure F, followed by purification by chromatography (silica; EtOAc), yielded 41 as a 
Page 41 of 75
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
yellow solid (201 mg, 100%); Rf 0.27 (100% EtOAc); mp 140-160 °C (dec); UV λmax (EtOH) 243 
nm; IR (cm-1) 3414, 3111, 3072, 2920, 2110, 1704; 1H NMR (500 MHz, DMSO-d6) δ 4.86 (1H, s, 
C≡CH), 6.91-6.96 (1H, m, H-4'), 7.29 (2H, dd, J = 7.6, 8.0 Hz, H-3' and H-5'), 7.80 (2H, dd, J = 
2.0, 8.0 Hz, H-2' and H-6'), 8.30 (1H, s, H-8), 9.70 (1H, s, NH), 13.17 (1H, br, NH); 13C NMR (125 
MHz, DMSO-d6) δ 87.0 (C≡CH), 118.3 (Ar-C), 120.0 (Ar-C), 128.4 (Ar-C), 140.8 (Ar-C), 156.2 
(Ar-C); HRMS calcd for C13H10N5 [M+H]
+ 236.0931, found 236.0934. 
4-(6-Ethynyl-9H-purin-2-ylamino)benzenesulfonamide (42). Deprotection of 40 (0.050 g, 0.11 
mmol) in accordance with general procedure F, followed by purification by chromatography 
(silica; 10% MeOH:DCM), afforded 42 as a beige solid (18 mg, 50%); mp 156-158 ºC; IR (cm-1) 
3347, 3255, 2920, 2848, 2118, 1568, 1529, 1477, 1128; UV λmax (EtOH) 356, 292, 215 nm;
 1H 
NMR (500 MHz, DMSO-d6) δ 4.90 (1H, s, C≡CH), 7.16 (2H, s, SO2NH2), 7.17 (2H, d, J = 9.0 Hz, 
H-2' and H-6'), 7.93 (2H, d, J = 9.0 Hz, H-3' and H-5'), 8.36 (1H, s, H-8); LRMS (ES+) m/z 315.1 
[M+H]+; HRMS calcd for C13H10N6O2S [M+H]
+ 315.0664, found 315.0687. Note: Insufficient 
material for 13C NMR analysis. 
6-Ethynyl-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (43). Deprotection of 37 (68 mg, 0.169 
mmol) in accordance with general procedure F, but using 1.2 mol equiv. of TBAF, followed by 
purification by chromatography (silica; 15-100% EtOAc:petrol), afforded 43 as an off-white solid 
(41 mg, 100%); Rf 0.32 (50% EtOAc:petrol); 
1H NMR (500 MHz, CDCl3) δ 1.58-1.63 (1H, m, 
CH), 1.63-1.78 (2H, m, CH2), 1.90-1.99 (1H, m, CH), 1.99-2.06 (1H, m, CH), 2.07-2.12 (1H, m, 
CH), 3.68-3.74 (1H, m, CH), 3.71 (1H, s, C≡CH), 4.09-4.14 (1H, m, CH), 5.65 (1H, dd, J = 2.6, 
10.8 Hz, NCH), 8.26 (1H, s, H-8); LRMS (ES+) m/z 247.0 [M+H]+. Note: Insufficient material for 
13C NMR analysis. 
6-Chloro-N-phenyl-9H-purin-2-amine (44). A mixture of N2-phenylguanine trifluoroacetate (15) 
(2.00 g, 5.87 mmol) and N,N-diethylaniline (1.9 mL, 11.73 mmol) in POCl3 (30 mL) was heated at 
115 °C for 60 min. The resultant yellow solution was carefully added dropwise to crushed ice-water 
with stirring, and the aqueous solution was neutralised by cautious addition of aqueous NaOH 
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solution (1.0 M). The aqueous mixture was extracted with EtOAc (2 × 20 mL), and the combined 
organic extracts were dried (Na2SO4) and evaporated under reduced pressure. Purification by 
chromatography (silica; 50% EtOAc:petrol) gave 44 as a white powder (670 mg, 46%); mp 172-174 
°C; UV λmax (EtOH) 329, 272 nm; IR (cm
-1) 3399, 3289, 1627, 1601, 1571, 1540; 1H NMR (500 
MHz, DMSO-d6) δ 6.89-6.92 (1H, t, J = 7.5 Hz, H-4'), 7.23-7.26 (2H, dd, J = 7.4, 7.5 Hz, H-3' and 
H-5'), 7.71-7.73 (2H, d, J = 7.4 Hz, H-2' and H-6'), 8.20 (1H, s, H-8), 9.81 (1H, br s, NH), 13.20 
(1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 118.6, 121.5, 128.5, 140.3, 142.4, 155.5; LRMS 
(ES+) m/z 246.1 [M+H]+. 
6-Chloro-N-phenyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (45). To a solution of 44 
(0.2 g, 0.82 mmol) and CSA (0.01 g, 0.041 mmol) in EtOAc (25 mL) was added DHP (83 µL, 0.90 
mmol), and the mixture was heated at 75 °C for 17 h. After cooling, the pH was adjusted to 8-9 with 
concentrated aqueous ammonia, and the volatiles were removed in vacuo. Purification by 
chromatography (silica; 1/2 to 2/1 EtOAc:petrol) furnished 45 as a waxy solid (194 mg, 72%); mp 
194-196 °C; UV λmax (EtOH) 330, 275 nm; IR (cm
-1) 3274, 3106, 2934, 2849, 1579, 1573, 1535; 1H 
NMR (500 MHz, DMSO-d6) δ 1.38-1.39 (2H, m, CH2), 1.49-1.54 (1H, m, CH), 1.76-1.80 (2H, m, 
CH2), 2.09-2.17 (1H, m, CH), 3.43-3.48 (1H, m, CH), 3.81-3.83 (1H, m, CH), 5.38-5.40 (1H, dd, J 
= 2.0, 11.0 Hz, NCH), 6.74-6.77 (1H, t, J = 8.5 Hz, H-4'), 7.07-7.11 (2H, dd, J = 7.5, 8.5 Hz, H-3' 
and H-5'), 7.56-7.58 (2H, d, J = 7.5 Hz, H-2' and H-6'), 8.26 (1H, s, H-8), 9.79 (1H, br s, NH), 
13.21 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 24.5, 29.4, 54.9, 67.7, 81.6, 118.7, 121.7, 
124.7, 128.6, 140.1, 142.4, 149.3, 152.7, 155.3; LRMS (ES+) m/z 329.7 [M+H]+. 
N-Phenyl-6-(prop-1-yn-1-yl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (46). A 
suspension of 45 (0.1 g, 0.30 mmol), PdCl2(CH3CN)2 (0.8 mg, 0.003 mmol), 
dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl (4.3 mg, 0.009 mmol) and Cs2CO3 (0.26 g, 
0.79 mmol) in acetonitrile (1 mL) was degassed for 10 min under a nitrogen atmosphere at room 
temperature. While degassing, an excess of methylacetylene was condensed and added to the 
reaction mixture via a cannula, and the reaction mixture was heated and stirred at 40 °C for 2.5 h. 
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After cooling to room temperature, water (5 mL) was added and the mixture was extracted with 
EtOAc (3 × 15 mL). The combined organic extracts were washed with brine (10 mL), dried 
(MgSO4), and the solvent was evaporated under reduced pressure. Purification by chromatography 
(silica; 30%-80% EtOAc:petrol) gave 46 as a colourless glassy compound (78 mg, 77%); Rf 0.27 
(30% EtOAc:petrol); 1H NMR (500 MHz, CDCl3) δ 1.62-1.85 (3H, m, CH2 and CH), 2.06-2.15 
(3H, m, CH2 and CH), 2.23 (3H, s, C≡CCH3), 3.74-3.81 (1H, m, CH), 4.15-4.21 (1H, m, CH), 5.60-
5.67 (1H, m, CH), 7.04 (1H, dd, J = 7.4, 7.3 Hz, H-4'), 7.34 (2H, dd, J = 8.5, 7.4 Hz, H-2' and H-6'), 
7.47 (1H, s, NH), 7.34 (2H, dd, J = 8.6, 0.9 Hz, H-3' and H-5'), 8.03 (1H, s, H-8); LRMS (ES+) m/z 
334.0 [M+H]+. Note: Insufficient material for 13C NMR analysis. 
N-Phenyl-6-(phenylethynyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (47). To a 
degassed suspension of 45 (0.1 g, 0.30 mmol), PdCl2(CH3CN)2 (0.8 mg, 0.003 mmol), 
dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl (4.3 mg, 0.009 mmol) and Cs2CO3 (0.26 g, 
0.79 mmol) in anhydrous acetonitrile (1 mL) was added an excess of phenylacetylene, and the 
mixture was heated at 80 °C for 2 h. After cooling, water (5 mL) was added and the suspension was 
extracted with EtOAc (3 × 15 mL). The combined organic extract was washed with brine (10 mL), 
dried (MgSO4), and the solvent was removed in vacuo. Purification by chromatography (silica; 0-
80% EtOAc:petrol) gave 47 as a colourless glassy compound (94 mg, 78%); Rf 0.53 (65% 
EtOAc:petrol); 1H NMR (500 MHz, CDCl3) δ 1.64-1.88 (3H, m, CH2 and CH), 2.07-2.19 (3H, m, 
CH2 and CH), 3.74-3.84 (1H, m, CH), 4.16-4.24 (1H, m, CH), 5.63-5.71 (1H, m, CH), 7.03-7.08 
(1H, m, H-4'), 7.32-7.46 (5H, m, phenyl), 7.50 (1H, s, NH), 7.70 (2H, d, J = 8.3 Hz, H-2' and H-6'), 
7.72-7.75 (2H, m, H-3' and H-5'), 8.08 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 22.9, 25.0, 
31.5, 68.8, 82.2, 84.1, 97.6, 118.9, 121.5, 122.5, 128.5, 129.0, 129.4, 130.0, 132.9, 139.8, 141.0, 
142.3, 152.5, 156.2; LRMS (ES+) m/z 396.4 [M+H]+. 
N-Phenyl-6-(prop-1-yn-1-yl)-9H-purin-2-amine (48). Prepared in accordance with general 
procedure E from 46 (0.061 g, 0.18 mmol). Recrystallisation from EtOAc-petrol gave 48 as a pale 
yellow solid (18 mg, 40%); mp 155-158 °C (dec); UV λmax (EtOH) 272 nm; IR (cm
-1) 1529, 1577, 
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2236, 2919; 1H NMR (500 MHz, MeOD-d4) δ 2.12 (3H, s, C≡CCH3), 6.87 (1H, t, J = 7.3 Hz, H-4'), 
7.18 (2H, t, J = 7.8 Hz, H-2' and H-6'), 7.63 (2H, d, J = 7.9 Hz, H-3' and H-5'), 8.04 (1H, s, H-8); 
13C NMR (125 MHz, MeOD-d4) δ 4.3, 116.9, 119.2, 120.1, 122.9, 129.6, 163.2, 163.5; LRMS 
(ES+) m/z 250.1 [M+H]+; HRMS  calcd for C14H12N5 [M+H]
+ 250.1087, found 250.1085. 
N-Phenyl-6-(phenylethynyl)-9H-purin-2-amine (49). Prepared in accordance with general 
procedure E from 47 (0.055 g, 0.14 mmol). Recrystallisation from EtOAc-petrol gave 49 as a 
yellow solid (22 mg, 51%); mp 206-208 °C (dec); UV λmax (EtOH) 281 nm; IR (cm
-1) 1532, 1574, 
2208, 3226; 1H NMR (500 MHz, MeOD-d4) δ 6.79 (1H, t, J = 7.3 Hz, H-4'), 7.11 (2H, dd, J = 7.8, 
8.1 Hz, H-2' and H-6'), 7.23-7.32 (3H, m, H-3', H-5' and Ar-H), 7.54-7.58 (4H, m, 4 × ArH), 8.02 
(1H, s, H-8); 13C NMR (125 MHz, MeOD-d4) δ 97.3, 120.2, 122.8, 122.9, 129.6, 129.8, 131.2, 
133.5, 141.8, 158.6; LRMS (ES+) m/z 312.2 [M+H]+; HRMS  calculated for C19H14N5 [M+H]
+ 
312.1244, found 312.1242. 
6-Ethyl-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (50). To a solution of 43 (0.05 g, 0.20 
mmol) and quinoline (20 µL) in EtOAc (5 mL) was added Lindlar’s catalyst (10 mg, 20% w/w), 
and the mixture was stirred for 2 h under an atmosphere of H2. The suspension was filtered through 
Celite, eluting with methanol (30 mL), and volatiles were removed in vacuo. Purification by 
chromatography (silica; 50% EtOAc:petrol) yielded 50 as a colourless oil (50 mg, 99%); UV λmax 
(EtOH) 264 nm; IR (cm-1) 2946, 2860, 2364, 2338, 1604; 1H NMR (500 MHz, DMSO-d6) δ 1.35 
(3H, t, J = 7.5 Hz, CH3CH2), 1.59 (2H, m, CH2), 1.97 (1H, m, CH), 1.99 (2H, d, J = 10.5 Hz, CH2), 
2.50 (1H, m, CH), 3.01 (2H, q, J = 7.5 Hz, CH3CH2), 3.73 (1H, m, CH), 4.04 (1H, d, J = 10.5 Hz, 
CH), 5.69 (1H, d, J = 10.5 Hz, CH), 8.74 (1H, s, H-8); 13C NMR (500 MHz, DMSO-d6) δ 12.3, 
22.7, 24.8, 26.5, 31.8, 68.9, 82.1, 142.1, 157.9, 159.6, 167.4, 167.5; LRMS (ES+) m/z  251.0 
[M+H]+. 
6-Ethyl-2-fluoro-9H-purine (51). Prepared in accordance with general procedure E from 50 
(0.18 g, 0.72 mmol). Purification by chromatography (silica; 25% EtOAc:petrol) yielded 51 as a 
white solid (0.117 g, 98%); mp 146-148 °C; UV λmax (EtOH) 269 nm; IR (cm
-1) 1676, 1616, 1573; 
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1H NMR (400 MHz, DMSO-d6) δ 1.30 (3H, t, J = 7.5 Hz, CH3CH2), 3.00 (2H, q, J = 7.5 Hz, 
CH3CH2), 8.17 (1 H, s, H-8); 
13C NMR (125 MHz, DMSO-d6) δ 11.7, 25.9, 68.3, 116.0, 118.4, 
146.4, 158.0 (d, JC-F = 206.0 Hz), 158.3 (d, JC-F = 31.5 Hz); LRMS (ES
+) m/z  167.7 [M+H]+. 
4-(6-Ethyl-9H-purin-2-ylamino)benzenesulfonamide (52). Prepared by general procedure A 
from 51 (0.081 g, 0.49 mmol), following purification by chromatography (silica; 50% 
EtOAc:petrol), as a white solid (33 mg, 21%); mp 291-293 ºC; UV λmax (EtOH) 318, 287, 212 nm; 
IR (cm-1) 3377, 3060, 2852, 1388, 1158; 1H NMR (500 MHz, DMSO-d6) δ 1.35 (3H, t, J = 6.0 Hz, 
CH3CH2), 3.00 (2H, q, J = 6.0 Hz, CH3CH2), 7.14 (2H, br s, SO2NH2), 7.69 (2H, d, J = 7.5 Hz, H-2' 
and H-6'), 7.99 (2H, d, J = 7.5 Hz, H-3' and H-5'), 8.17 (1H, s, H-8), 9.89 (1H, br s, NH); 13C NMR 
(125 MHz, DMSO-d6) δ 12.3, 26.0, 117.0, 118.9, 125.4, 126.4, 135.2, 141.2, 144.4, 154.0, 155.5; 
LRMS (ES+) m/z 318.6 [M+H]+; HRMS calcd for C13H14N6O2S [M+H]
+ 319.097076, found 
319.09788. 
6-Cyclopropyl-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (53). The title compound was 
prepared from 36 (0.04 g, 0.27 mmol) and potassium cyclopropyltrifluoroborate (50 mg, 0.19 
mmol) following general procedure G. Purification by chromatography (silica; 50% 
EtOAc:petrol) afforded 53 as a colourless oil (21 mg, 42%); UV λmax (EtOH) 211, 325, 391 nm; IR 
(cm-1) 2986; 1H NMR (400 MHz, DMSO-d6) δ 1.25 (4H, d, J = 6.5 Hz, cyclopropyl 2 × CH2), 1.55 
(2H, m, CH2), 1.72 (1H, m, CH), 1.95 (2H, d, J = 10.5 Hz, CH2), 2.27 (1H, m, CH), 2.67 (1H, m, 
cyclopropyl CH), 3.70 (1H, m, CH), 3.99 (1H, d, J = 10.5 Hz, CH), 5.63 (1H, d, J = 10.5 Hz, CH), 
8.70 (1H, s, H-8); 13C NMR (500 MHz, DMSO-d6) δ 11.9, 13.2, 22.2, 24.4, 29.7, 67.7, 81.3, 130.9, 
144.1, 151.8, 157.6, 159.8, 176.9; LRMS (ES+) m/z  262.4 [M+H]+. 
6-Cyclopropyl-2-fluoro-9H-purine (54). The title compound was prepared from 53 (0.19 g, 0.72 
mmol) employing general procedure E. Purification by chromatography (silica; EtOAc) afforded 
54 as a white solid (0.12 g, 95%); mp 137-139 °C; UV λmax (EtOH) 323, 213 nm; IR (cm
-1) 3062; 
1H NMR (400 MHz, DMSO-d6) δ 1.11 (4H, d, J = 6.5 Hz, cyclopropyl 2 × CH2), 2.51 (1H, m, 
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cyclopropyl CH), 8.40 (1H, s, H-8); 13C NMR (400 MHz, DMSO-d6) δ 11.6, 13.1, 131.2, 144.2, 
151.8, 157.6, 159.8; LRMS (ES+) m/z 179.0 [M+H]+. 
4-(6-Cyclopropyl-9H-purin-2-ylamino)benzenesulfonamide (55). Synthesised following general 
procedure A from 54 (0.086 g, 0.49 mmol). Purification by chromatography (silica; EtOAc) 
afforded 55 as a pale yellow solid (24 mg, 15%); mp 291-293 ºC; UV λmax (EtOH) 315.5, 289, 213 
nm; IR (cm-1) 3389, 3062, 2921, 2851, 1727, 1604, 1579, 1531, 1379, 1149; 1H NMR (500 MHz, 
DMSO-d6) δ 1.23 (4H, d, J = 6.5 Hz, cyclopropyl 2 × CH2), 1.35 (1H, m, cyclopropyl CH), 7.18 
(2H, br s, SO2NH2), 7.74 (2H, d, J = 8.0 Hz, H-2' and H-6'), 7.99 (2H, d, J = 8.0 Hz, H-3' and H-5'), 
8.22 (1H, s, H-8), 9.75 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 10.5, 13.0, 117.1, 126.4, 
126.6, 141.1, 144.4, 151.8, 155.5, 162.9; LRMS (ES+) m/z 331.1 [M+H]+; HRMS calcd for 
C14H15N6O2S [M+H]
+ 331.0977, found 331.0980. 
2-Fluoro-6-phenyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (56). Synthesised in accordance 
with general procedure G from 36 (0.20 g, 0.78 mmol) and phenylboronic acid (0.133 g, 1.09 
mmol). Purification by chromatography (silica; 20% EtOAc:petrol) gave 56 as a white solid (0.30 g, 
95%); mp 138-140 ºC; UV λmax (EtOH) 306, 269, 203 nm; IR (cm
-1) 3117, 2956, 2858, 1586; 1H 
NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 (2H, m, CH2), 2.29 (1H, 
s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 4.04 (1H, d, J = 12.0 Hz, CH), 5.74 (1H, d, J = 12.0 Hz, CH), 
7.64, (3H, m, H-3'', H-4'' and H-5''), 8.79 (2H, dd, J = 3.0, 7.5 Hz, H-2'' and H-6''), 8.25 (1H, s, H-
8); 13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.7, 67.7, 81.3, 128.9, 129.3, 129.5, 132.0, 
134.0, 145.4, 154.3 (d, JC-F = 17.5 Hz), 155.5 (d, JC-F = 144.0 Hz), 157.0, 158.7; LRMS (ES
+) m/z 
299.3 [M+H]+. 
2-Fluoro-6-(3-methoxyphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (57). Prepared 
according to general procedure G from 36 (0.20 g, 0.78 mmol) and 4-methoxyphenylboronic acid 
(0.16 g, 1.09 mmol). Purification by chromatography (silica; 30% EtOAc:petrol) gave 57 as a white 
solid (0.29 g, 80%); mp 133-135 ºC; UV λmax (EtOH) 306, 271, 204 nm; IR (cm
-1) 3089, 2938, 
2857, 1761, 1586, 1516; 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 
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2.02 (2H, m, CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 3.89 (3H, s, OCH3), 4.04 (1H, 
d, J = 12.0 Hz, CH), 5.74 (1H, d, J = 12.0 Hz, CH), 7.18 (1H, m, H-2''), 7.50-7.55 (1H, m, H-5''), 
8.45-8.49 (2H, m, H-4'', H-6''), 8.78 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 
29.7, 55.3, 67.7, 81.3, 114.4, 117.9, 122.0, 129.4, 130.0, 135.3, 145.4, 154.3 (d, JC-F = 17.5 Hz), 
155.0 (d, JC-F = 160.0 Hz), 156.9, 158.6, 159.4; LRMS (ES
+) m/z 334.2 [M+H]+. 
2-Fluoro-6-(4-methoxyphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (58). Synthesised in 
accordance with general procedure G from 36 (0.20 g, 0.78 mmol) and 4-methoxyphenylboronic 
acid (0.16 g, 1.09 mmol). Purification by chromatography (silica; 30% EtOAc:petrol) afforded 58 
as a white solid (0.35 g, 98%); mp 131-133 ºC; UV λmax (EtOH) 306, 271, 204 nm; IR (cm
-1) 3089, 
2938, 2857, 1761, 1586, 1516; 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, 
CH), 2.02 (2H, m, CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 3.88 (3H, s, OCH3), 4.04 
(1H, d, J = 12.0 Hz, CH), 5.74 (1H, d, J = 12.0 Hz, CH), 7.15-7.18 (2H, d, J = 9.0 Hz, H-3'' and H-
5''), 8.79-8.81 (2H, d, J = 9.0 Hz, H-2'' and H-6''), 8.85 (1H, s, H-8); 13C NMR (125 MHz, DMSO-
d6) δ 22.2, 24.4, 29.7, 55.5, 67.7, 81.2, 114.3, 126.5, 128.5, 131.5, 144.7, 153.9 (d, JC-F = 17.5 Hz), 
155.2 (d, JC-F = 160.0 Hz), 157.0, 158.7, 162.4; LRMS (ES
+) m/z 329.2 [M+H]+. 
6-(3-Biphenyl)-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (59). Prepared following 
general procedure G from 36 (0.20 g, 0.78 mmol) and 3-biphenylboronic acid (0.22 g, 1.09 
mmol). Purification by chromatography (silica; 20% EtOAc:petrol) furnished 59 as a pale yellow 
solid (0.33 g, 80%); mp 221-223 ºC; UV λmax (EtOH) 346, 274 nm; IR (cm
-1) 2992, 2844, 2601, 
1589; 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 (2H, m, CH2), 
2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 4.04 (1H, d, J = 12.0 Hz, CH), 5.79 (1H, d, J = 
12.0 Hz, CH), 7.45 (1H, d, J = 7.0 Hz, H-6''), 7.56 (1H, dd, J = 7.0, 7.1 Hz, H-5''), 7.78 (5H, m, 
Ph), 8.40 (1H, s, H-2''), 8.84 (1H, d, J = 7.1 Hz, H-4''), 9.18 (1H, s, H-8); 13C NMR (125 MHz, 
DMSO-d6) δ 22.2, 24.4, 29.7, 67.7, 81.3, 126.8, 127.8, 127.9, 128.4, 129.1, 129.5, 129.6, 130.3, 
134.7, 139.6, 140.8, 145.6, 154.4 (d, JC-F = 17.5 Hz), 155.2 (d, JC-F = 116.0 Hz), 157.0, 158.5; 
LRMS (ES+) m/z 375.1 [M+H]+. 
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2-Fluoro-6-(3-piperonyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (60). Synthesised in 
accordance with general procedure G from 36 (0.20 g, 0.78 mmol) and 3,4-
(methylenedioxy)phenylboronic acid (0.18 g, 1.09 mmol). Purification by chromatography (silica; 
30% EtOAc:petrol) yielded 60 as a white solid (0.21 g, 56%); mp 151-153 °C; UV λmax (EtOH) 351, 
284 nm; IR (cm-1) 3011, 2917, 1721, 1616, 1511; 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, 
CH2), 1.76 (1H, m, CH), 2.02 (2H, m, CH2), 2.29 (1H, s, CH), 3.73 (1H, t, J = 12.0 Hz, CH), 4.04 
(1H, d, J = 12.0 Hz, CH), 5.73 (1H, d, J = 12.0 Hz, CH), 6.17 (2H, s, OCH2O), 7.14-7.17 (1H, d, J 
= 8.0 Hz, H-5''), 8.28 (1H, s, H-2''), 8.48-8.51 (1H, d, J = 8.0 Hz, H-6''), 8.82 (1H, s, H-8); 13C 
NMR (125 MHz, DMSO-d6) δ  22.2, 24.4, 29.7, 67.7, 81.2, 101.9, 108.6, 125.4, 128.0, 128.6, 
144.9, 147.8, 150.6, 154.1, 154.8, 156.9, 158.7; LRMS (ES+) m/z 343.1 [M+H]+. 
6-(4-Dibenzofuryl)-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (61). Prepared according 
to general procedure G from 36 (0.20 g, 0.78 mmol) and 4-dibenzofuranboronic acid (0.23 g, 1.09 
mmol). Purification by chromatography (silica; 30% EtOAc:petrol) yielded 61 as a cream solid 
(0.39 g, 92%); mp 168-170 ºC; UV λmax (EtOH) 398, 256, 202 nm; IR (cm
-1) 3092, 2589, 1579; 1H 
NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 (2H, m, CH2), 2.29 (1H, 
s, CH), 3.77 (1H, t, J = 12 Hz, CH), 4.04 (1H, d, J = 12.0 Hz, CH), 5.79 (1H, d, J = 12.0 Hz, CH), 
7.45-7.47 (1H, dd, J = 7.0, 7.1 Hz, H-2''), 7.52-7.62 (1H, dd, J = 8.0, 8.1 Hz, H-7''), 7.61-7.71 (1H, 
dd, J = 8.0, 8.1 Hz, H-8''), 7.76-7.79 (1H, d, J = 8.0 Hz, H-9''), 8.25-8.27 (1H, d, J = 7.1 Hz, H-3''), 
8.42-8.44 (1H, d, J = 8.0 Hz, H-6''), 8.55-8.58 (1H, d, J = 7.5 Hz, H-1''), 8.93 (1H, s, H-8); 13C 
NMR (125 MHz, DMSO-d6) δ 22.2, 24.5, 29.7, 67.8, 68.3, 81.4, 111.9, 119.3, 121.3, 122.9, 123.1, 
123.4, 124.3, 125.2, 128.1, 130.1, 145.6, 153.1, 154.7 (d, JC-F = 18.0 Hz), 155.7 (d, JC-F = 160.0 
Hz), 156.9, 158.5; LRMS (ES+) m/z 389.4 [M+H]+. 
2-Fluoro-6-(1-thianthrenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (62). Prepared in 
accordance with general procedure G from 36 (0.20 g, 0.78 mmol) and 1-thianthreneboronic acid 
(0.28 g, 1.09 mmol). Purification by chromatography (silica; 30% EtOAc:petrol) afforded 62 as an 
orange solid (0.43 g, 90%); mp 164-166 ºC; UV λmax (EtOH) 396, 224 nm; IR (cm
-1) 3092, 2814, 
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2589, 1611, 1497; 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 
(2H, m, CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 4.04 (1H, d, J = 12.0 Hz, CH), 5.79 
(1H, d, J = 12.0 Hz, CH), 7.21-7.30 (1H, dd, J = 7.4, 7.5 Hz, H-3''), 7.31-7.39 (1H, dd, J = 7.5, 7.6 
Hz, H-7''), 7.37-7.45 (1H, d, J = 7.5 Hz, H-9''), 7.51-7.58 (1H, dd, J = 7.5, 7.6 Hz, H-8''), 7.59-7.65 
(1H, d, J = 7.5 Hz, H-6''), 7.79 (1H, d, J = 7.4 Hz, H-2''), 7.89 (1H, d, J = 7.5 Hz, H-4''), 8.93 (1H, 
s, H-8); 13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.5, 67.7, 68.3, 81.5 127.5, 128.2, 128.5, 
128.7, 128.9, 130.6, 130.9, 131.4, 134.5, 134.7, 135.1, 135.5, 136.4, 146.2, 153.8 (d, JC-F = 17.5 
Hz), 156.2, 155.0 (d, JC-F = 150.0 Hz), 157.2; LRMS (ES
+) m/z 437.2 [M+H]+. 
2-Fluoro-6-phenyl-9H-purine (63). Prepared from 56 (0.22 g, 0.72 mmol) following general 
procedure E. Repeated trituration of the precipitated solid with water gave 63 (0.14 g, 90%); mp 
273-275 °C; UV λmax (EtOH) 349 nm; IR (cm
-1) 2820, 1599, 1560; 1H NMR (300 MHz, DMSO-d6) 
δ 7.62 (3H, m, H-3'', H-4'' and H-5''), 8.68 (1 H, s, H-8), 8.81 (2H, m, H-2'' and H-6''); 13C NMR 
(125 MHz, DMSO-d6) δ 128.8, 129.4, 131.7, 134.4, 145.7, 154.4, 156.0, 157.1, 158.7; LRMS (ES
+) 
m/z 214.6 [M+H]+. 
2-Fluoro-6-(3-methoxyphenyl)-9H-purine (64). Deprotection of 57 (0.24 g, 0.72 mmol) in 
accordance with general procedure E afforded the title compound 64 (0.17 g, 98%) following 
repeated trituration of the precipitated solid with water; mp 237-238 °C; UV λmax (EtOH) 251 nm; 
IR (cm-1) 2837, 1864, 1587, 1565; 1H NMR (300 MHz, DMSO-d6) δ 3.89 (3H, s, OCH3), 7.18 (1 H, 
s, H-2''), 7.50-7.55 (1H, m, H-5''), 8.37 (1H, s, H-8), 8.45-8.49 (2H, m, H-4'', H-6''); 13C NMR (125 
MHz, DMSO-d6) δ 55.3, 114.2, 117.6, 121.8, 130.0, 135.7, 146.3, 154.3, 157.2, 158.6, 159.4; 
LRMS (ES+) m/z 245.5 [M+H]+. 
2-Fluoro-6-(4-methoxyphenyl)-9H-purine (65). Synthesised in accordance with general 
procedure E from 58 (0.24 g, 0.72 mmol). Trituration of the precipitated solid with water furnished 
65 as a pale yellow solid (0.17 g, 95%); mp 212-214 °C; UV λmax (EtOH) 204 nm; IR (cm
-1) 2845, 
1586; 1H NMR (300 MHz, DMSO-d6) δ 3.88 (3H, s, OCH3), 7.15-7.18 (2H, d, J = 9.0 Hz, H-3'' and 
H-5''), 8.60 (1H, s, H-8), 8.79-8.81 (2H, d, J = 9.0 Hz, H-2'' and H-6''); 13C NMR (500 MHz, 
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DMSO-d6) δ 55.4, 114.1, 114.3, 126.8, 127.5, 131.3, 145.3, 157.1, 158.8, 162.2; LRMS (ES
+) m/z 
245.2 [M+H]+. 
6-(Biphenyl-3-yl)-2-fluoro-9H-purine (66). The title compound was prepared according to 
general procedure E from 59 (0.27 g, 0.72 mmol). Repeated washing of the precipitated solid with 
water gave 66 (0.20 g, 97%); mp 245-247 °C; UV λmax (EtOH) 349 nm; IR (cm
-1) 1607, 1568; 1H 
NMR (300 MHz, DMSO-d6) δ 7.43-7.45 (1H, d, J = 7.0 Hz, H-6''), 7.54-7.58 (1H, dd, J = 6.9, 7.0 
Hz, H-5''), 7.74-7.81 (5H, m, Ph), 8.40 (1H, s, H-2''), 8.80-8.85 (1H, d, J = 6.9 Hz, H-4''), 8.91 (1H, 
s, H-8); 13C NMR (125 MHz, DMSO-d6) δ 126.8, 127.7, 127.9, 128.2, 129.1, 129.5, 130.0, 135.0, 
139.7, 140.7, 146.1 (m, JC-F), 157.1, 158.7; LRMS (ES
+) m/z 291.1 [M+H]+. 
6-(Benzo[d][1,3]dioxol-5-yl)-2-fluoro-9H-purine (67). Deprotection of 60 (0.25 g, 0.72 mmol) 
was achieved following general procedure E. Trituration of the white solid that precipitated 
yielded 67 (0.16 g, 87%); mp 165-167 °C; UV λmax (EtOH) 351, 292 nm; IR (cm
-1) 2955, 2859, 
1601, 1570, 1504; 1H NMR (300 MHz, DMSO-d6) δ 6.17 (2H, s, OCH2O), 7.18-7.18 (1H, d, J = 
8.0 Hz, H-5''), 8.28 (1H, s, H-2''), 8.48-8.51 (1H, d, J = 8.0 Hz, H-6''), 8.63 (1H, s, H-8); 13C NMR 
(125 MHz, DMSO-d6) δ 101.9, 108.6, 125.1, 128.4, 145.3, 147.8, 150.3, 153.9 (d, JC-F = 17.5 Hz), 
156.0 (d, JC-F = 150.0 Hz), 157.0, 158.6; LRMS (ES
+) m/z 259.2 [M+H]+. 
6-(4-Dibenzofuranyl)-2-fluoro-9H-purine (68). The title compound was prepared in accordance 
with  general procedure E from 61 (0.28 g, 0.72 mmol), and purified by repeated washing with 
water to afford 68 as an off-white solid (0.20 g, 94%); mp 266-268 °C; UV λmax (EtOH) 250 nm; IR 
(cm-1) 3020, 2923, 2832, 1867, 1611, 1568; 1H NMR (300 MHz, DMSO-d6) δ 7.45-7.48 (1H, dd, J 
= 7.0, 7.1 Hz, H-2''), 7.55-7.63 (1H, dd, J = 7.9, 8.0 Hz, H-7''), 7.61-7.68 (1H, dd, J = 7.9, 8.0 Hz, 
H-8''), 7.76-7.79 (1H, d, J = 8.0 Hz, H-9''), 8.26-8.29 (1H, d, J = 7.1 Hz, H-3''), 8.43-8.45 (1H, d, J 
= 8.0 Hz, H-6''), 8.55-8.58 (1H, d, J = 7.0 Hz, H-1''), 8.78 (1H, s, H-8); 13C NMR (500 MHz, 
DMSO-d6) δ 112.1, 121.3, 123.0, 123.5, 124.0, 125.0, 128.0, 130.0, 155.7; LRMS (ES
+) m/z 305.1 
[M+H]+. 
Page 51 of 75
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
2-Fluoro-6-(thianthren-1-yl)-9H-purine (69). Synthesised following general procedure E from 
62 (0.32 g, 0.72 mmol), and purified by repeated trituration with water to give 69 (0.36 g, 93%); mp 
166-168 °C; UV λmax (EtOH) 250 nm; IR (cm
-1) 3068, 2817, 2572, 1609, 1511; 1H NMR (300 MHz, 
DMSO-d6) δ 7.21-7.29 (1H, dd, J = 7.4, 7.5 Hz, H-3''), 7.31-7.38 (1H, dd, J = 7.5, 7.6 Hz, H-7''), 
7.39-7.46 (1H, d, J = 7.5 Hz, H-9''), 7.49-7.55 (1H, dd, J = 7.5, 7.6 Hz, H-8''), 7.58-7.64 (1H, d, J = 
7.5 Hz, H-6''), 7.79 (1H, d, J = 7.5 Hz, H-2''), 7.88-7.91 (1H, d, J = 7.4 Hz, H-4''), 8.31 (1H, s, H-
8); 13C NMR (125 MHz, DMSO-d6) δ  124.6, 127.5, 128.2, 128.4, 128.7, 128.9, 130.5, 131.1, 
134.7, 134.9, 156.4, 159.9, 160.5; LRMS (ES+) m/z 353.1 [M+H]+. 
4-(6-Phenyl-9H-purin-2-ylamino)benzenesulfonamide (70). The title compound was synthesised 
according to general procedure A from 63 (0.10 g, 0.49 mmol). Purified by chromatography 
(silica; 50% EtOAc:petrol) to give 70 as a white solid (80 mg, 45%); mp 153-155 ºC; UV λmax 
(EtOH) 349, 294 nm; IR (cm-1) 3313, 2922, 2852, 1706, 1589, 1569, 1524, 1373, 1144; 1H NMR 
(300 MHz, DMSO-d6) δ 7.17 (2 H, br s, SO2NH2), 7.60 (3H, m, H-3'', H-4'' and H-5''), 7.75-7.78 
(2H, d, J = 8.5 Hz, H-2' and H-6'), 8.03-8.06 (2H, d, J = 8.5 Hz, H-3' and H-5') 8.37 (1H, s, H-8), 
8.94 (2H, m, H-2'' and H-6''), 9.91 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 117.2, 125.4, 
126.5, 128.5, 129.3, 130.8, 135.4, 135.8, 142.6, 144.3, 153.0, 154.6, 155.3; LRMS (ES+) m/z 367.2 
[M+H]+; HRMS calcd for C17H14N6O2S [M+H]
+ 367.0972, found 367.0974. 
4-(6-(3-Methoxyphenyl)-9H-purin-2-ylamino)benzenesulfonamide (71). Prepared in accordance 
with general procedure A from 64 (0.12 g, 0.49 mmol), and purified by chromatography (silica; 
50% EtOAc:petrol) to furnish 71 as a white solid (64 mg, 33%); mp 288-290 ºC; UV λmax (EtOH) 
294 nm; IR (cm-1) 3377, 3097, 3020, 2838, 1729, 1597, 1566, 1531, 1365, 1145; 1H NMR (300 
MHz, DMSO-d6) δ 3.89 (3H, s, OCH3), 7.17 (2H, s, SO2NH2), 7.18 (1H, s, H-2''), 7.50-7.55 (1H, 
m, H-5''), 7.74-7.77 (2H, d, J = 8.0 Hz, H-2' and H-6'), 8.03-8.06 (2H, d, J = 8.0 Hz, H-3' and H-5'), 
8.37 (1H, s, H-8), 8.45-8.49 (2H, m, H-4'' and H-6''); 13C NMR (125 MHz, DMSO-d6) δ 55.2, 
114.2, 116.6, 117.2, 121.8, 126.5, 129.6, 135.4, 137.1, 144.3, 146.3, 155.2, 115.6, 159.3; LRMS 
(ES+) m/z 397.3 [M+H]+; HRMS calcd for C18H16N6O3S [M+H]
+ 397.1077, found 397.1071.  
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4-(6-(4-Methoxyphenyl)-9H-purin-2-ylamino)benzenesulfonamide (72). Synthesed following 
general procedure A from 65 (0.12 g, 0.49 mmol) and isolated by chromatography (silica; 50% 
EtOAc:petrol) to yield 72 as a white solid (90 mg, 46%); mp 172-174 ºC; UV λmax (EtOH) 301, 203 
nm; IR (cm-1) 3322, 2133, 2005, 1594, 1533, 1514, 1352, 1147; 1H NMR (300 MHz, DMSO-d6) 
δ 3.88 (3H, s, OCH3), 7.17 (2H, br s, SO2NH2), 7.18 (2H, d, J = 8.5 Hz, H-3'' and H-5''), 7.74-7.77 
(2H, d, J = 8.0 Hz, H-2' and H-6'), 8.02-8.05 (2H, d, J = 8.0 Hz, H-3' and H-5'), 8.32 (1H, s, H-8), 
8.84-8.87 (2H, d, J = 8.5 Hz, H-2'' and H-6''); 13C NMR (125 MHz, DMSO-d6) δ 55.4, 114.0, 117.2, 
124.8, 126.5, 128.2, 131.0, 135.3, 142.0, 144.4, 152.8, 154.3, 155.3, 161.5; LRMS (ES+) m/z 397.3 
[M+H]+; HRMS calcd for C18H16N6O3S [M+H]
+ 397.1077, found 397.1071.  
4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino)benzenesulfonamide (73). Treatment of 66 
(0.14 g, 0.49 mmol) in accordance with general procedure A, with purification by chromatography 
(silica; EtOAc) afforded 73 as a white solid (46 mg, 21%); mp 153-155 ºC; UV λmax (EtOH) 349, 
294 nm; IR (cm-1) 3313, 2922, 2852, 1706, 1589, 1569, 1524, 1373, 1144; 1H NMR (300 MHz, 
DMSO-d6) δ 7.18 (1H, br s, SO2NH2), 7.39-7.50 (1H, d, J = 7.0 Hz, H-6''), 7.50-7.62 (1H, dd, J = 
7.0, 7.1 Hz, H-5''), 7.66-7.83 (5H, m, Ph), 7.83-7.93 (2H, d, J = 8.0 Hz, H-2' and H-6'), 8.00-8.13 
(2H, d, J = 8.0 Hz, H-3' and H-5'), 8.35-8.40 (1H, s, H-2''), 8.78-8.93 (1H, d, J = 7.1 Hz, H-4''), 
9.18 (1H, s, H-8), 10.00 (1H, br s, NH); LRMS (ES+) m/z 367.2 [M+H]+; HRMS calcd for 
C23H18N6O2S [M+H]
+ 367.0972, found 367.0974; HPLC: >96%, XSELECT column, retention time 
7.48 min, reverse phase, H2O/MeCN/ HCOOH gradient run, 1 mL min
−1. 
4-(6-(Benzo[d][1,3]dioxol-5-yl)-9H-purin-2-ylamino)benzenesulfonamide (74). The title 
compound was prepared following general procedure A from 67 (0.13 g, 0.49 mmol). Purification 
by chromatography (silica; EtOAc) gave 74 as a pale yellow solid (30 mg, 15%); mp 284-286 ºC; 
UV λmax (EtOH) 352, 295 nm; IR (cm
-1) 3174, 1573, 1526, 1408, 1350, 1153; 1H NMR (300 MHz, 
DMSO-d6) δ 6.14 (2H, s, OCH2O), 7.15 (2H, s, SO2NH2), 7.73-7.75 (2H, d, J = 8.0, H-2' and H-6'), 
7.98-8.01 (2H, d, J = 8.0 Hz, H-3' and H-5'), 8.31 (1H, s, H-8), 8.37 (1H, s, H-2''), 8.55 (2H, m, H-
5'' and H-6''), 9.89 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 101.6, 108.4, 108.6, 117.2, 
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124.7, 126.5, 129.9, 133.2, 135.5, 139.8, 142.2, 144.3, 147.6, 149.6, 151.9, 152.4, 154.4, 155.2; 
LRMS (ES+) m/z 443.3 [M+H]+; HRMS calcd for C18H14N6O4S [M+H]
+ 443.1285, found 443.1289.  
4-(6-(4-Dibenzofuryl)-9H-purin-2-ylamino)benzenesulfonamide (75). Synthesised in accordance 
with general procedure A from 68 (0.15 g, 0.49 mmol). Purification by chromatography (silica; 
50% EtOAc:petrol) gave 75 as a white solid (0.10 g, 47%); mp 213-215 ºC; UV λmax (EtOH) 292, 
250 nm; IR (cm-1) 3275, 3199, 3104, 2921, 2852, 1714, 1593, 1574, 1535, 1500, 1355, 1146; 1H 
NMR (300 MHz, DMSO-d6) δ 7.16 (2H, br s, SO2NH2), 7.44-7.53 (1H, dd, J = 6.9, 7.0 Hz, H-2''), 
7.54-7.68 (2H, m, H-7'' and H-8''), 7.68-7.74 (1H, d, J = 8.0 Hz, H-9''), 7.69-7.79 (2H, d, J = 8.0 
Hz, H-2' and H-6'), 8.18-8.26 (2H, d, J = 8.0 Hz, H-3' and H-5'), 8.23-8.32 (1H, d, J = 6.9 Hz, H-
3''), 8.38 (1H, s, H-8), 8.38-8.44 (1H, d, J = 7.5 Hz, H-6''), 8.49-8.58 (1H, d, J = 7.0 Hz, H-1''), 
10.07 (1H, br s, NH), 13.22 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 111.5, 117.3, 121.0, 
121.3, 122.9, 123.1, 123.2, 123.4, 124.9, 126.4, 128.0, 130.0, 135.4, 143.0, 144.4, 152.2, 153.0, 
154.4, 155.3, 155.7; LRMS (ES+) m/z 457.3 [M+H]+; HRMS calcd for C23H16N6O3S [M+H]
+ 
457.1077, found 457.1075. 
6-(4-Thianthren-1-yl)-9H-purin-2-ylamino)benzenesulfonamide (76). Synthesised following 
general procedure A from (69) (0.17 g, 0.49 mmol), and purified by chromatography (silica; 50% 
EtOAc:petrol) to furnish 76 as an orange solid (81 mg, 33%); mp 170-172 ºC; UV λmax (EtOH) 339, 
294, 250 nm; IR (cm-1) 3317, 2922, 2851, 1706, 1588, 1524, 1371, 1146; 1H NMR (300 MHz, 
DMSO-d6) δ 7.16 (2H, s, SO2NH2), 7.21-7.28 (1H, dd, J = 7.4, 7.5 Hz, H-3''), 7.30-7.36 (1H, dd, J 
= 7.5, 7.6 Hz, H-7''), 7.38-7.43 (1H, d, J = 7.5 Hz, H-9''), 7.48-7.53 (1H, dd, J = 7.5, 7.6 Hz, H-8''), 
7.58-7.63 (1H, d, J = 7.5 Hz, H-6''), 7.73 (2H, d, J = 8.5 Hz, H-2' and H-6'), 7.77-7.80 (1H, d, J = 
7.4 Hz, H-2''), 7.88-7.91 (1H, d, J = 7.5 Hz, H-4''), 8.06 (2H, d, J = 8.5 Hz, H-3' and H-5'), 8.34 
(1H, s, H-8); LRMS (ES+) m/z 505.2 [M+H]+; HRMS calcd for C23H16N6O2S3 [M+H]
+ 505.0570, 
found 505.0573. 
7-Chloro-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine (78). To a stirred solution of 
77 (0.04 g, 0.24 mmol) in anhydrous DMF (1 mL) was added anhydrous K2CO3 (36 mg, 0.26 
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mmol) and 4-methoxybenzyl chloride (34 µL, 0.25 mmol). The reaction mixture was stirred under 
N2 at 65 
oC for 18 h, and the solvent was removed under reduced pressure. The residual solid was 
redissolved in EtOAc (30 mL), washed with brine (3 × 30 mL), and the combined organic fractions 
were dried (Na2SO4) and the solvent was removed under reduced pressure. Purification by 
chromatography (silica; 40% EtOAc:petrol) afforded 78 as a light yellow solid (29 mg, 42 %); Rf 
0.21 (40% EtOAc:petrol); mp 105 oC; UV λmax (EtOH) 311 nm; IR (cm
-1) 3431, 3312, 3198, 3022, 
2940, 2798, 1571, 1513; 1H NMR (500 MHz, DMSO-d6) δ 3.71 (3H, s, OCH3), 5.22 (2H, s, CH2), 
6.24 (2H, br s, NH2), 6.48 (1H, s, H-5), 6.88 (2H, d, J = 8.7 Hz, H-2'' and H-6''), 7.23 (2H, d, J = 8.8 
Hz, H-3'' and H-5''), 8.07 (1H, s, H-2); 13C NMR (125 MHz, DMSO-d6) δ 45.4 (Ar-CH2-Ar), 55.1 
(OCH3), 103.8 (Ar-C), 114.0 (Ar-C), 124.4 (Ar-C), 128.7 (Ar-C), 129.2 (Ar-C), 133.9 (Ar-C), 
140.5 (Ar-C), 146.6 (Ar-C), 157.4 (Ar-C), 158.7 (Ar-C); HRMS calcd for C14H14ClN4O [M+H]
+ 
289.0851, found 289.0855. 
7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine (79). 
Synthesised following general method C from 78 (0.172 g, 0.60 mmol). The product was isolated 
by chromatography (silica; 80% EtOAc:petrol) to furnish 79 as a colourless oil (0.16 g, 0.45 mmol, 
75%); Rf 0.47 (20% EtOAc:Petrol); UV λmax (EtOH) 271 nm; IR (cm
-1) 3311, 2954, 2899, 2163, 
1672, 1598, 1516; 1H NMR (500 MHz, DMSO-d6) δ 0.90-1.87 (11H, m, cyclohexyl), 3.71 (3H, s, 
OCH3), 4.00 (2H, d, J = 6.7 Hz, OCH2), 5.17 (2H, br s, NH2), 5.24 (2H, s, CH2), 5.90 (1H, s, H-5), 
6.87 (2H, d, J = 8.7 Hz, H-2'' and H-6''), 7.20 (2H, d, J = 8.8 Hz, H-3'' and H-5''), 7.82 (1H, s, H-2); 
13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.1 (CH2), 37.0 (CH), 45.0 (Ar-CH2), 
55.1 (CH3), 73.3 (CH2), 87.5 (Ar-C), 113.9 (Ar-C), 118.2 (Ar-C), 128.7 (Ar-C), 129.7 (Ar-C),  
137.9 (Ar-C), 147.4 (Ar-C), 157.8 (Ar-C), 158.5 (Ar-C), 158.6 (Ar-C); HRMS calcd for 
C21H27N4O2 [M+H]
+
 367.2129, found 367.2132. 
7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-amine (80). A solution of 79 (0.035 g, 0.10 
mmol) in TFA (1 mL) was heated under reflux for 2 h, and the cooled solution was neutralised with 
saturated aqueous NaHCO3 (25 mL). The reaction mixture was extracted with EtOAc (3 × 30 mL), 
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and the combined organic fraction was dried (MgSO4) and evaporated under reduced pressure. 
Purification by chromatography (silica; 10% MeOH:DCM) to furnish 80 as a white solid (16.5 mg, 
70%); mp 99-102 oC; UV λmax (EtOH) 293, 244 nm; IR (cm
-1) 3447, 3323, 3187, 2923, 2850, 2795, 
2026, 1591, 1527; 1H NMR (500 MHz, CDCl3) δ 1.03-2.00 (11H, m, cyclohexyl), 4.03 (2H, d, J = 
6.1 Hz, OCH2), 4.37 (2H, br s, NH2), 5.91 (1H, s, H-5), 7.77 (1H, s, H-2), 9.89 (1H, br s, NH);
 13C 
NMR (125 MHz, CDCl3) δ 25.7, 26.4, 29.8, 37.5, 74.4, 88.1, 157.3; HRMS calcd for C13H19N4O 
[M+H]+ 247.1553, found 247.1556. 
7-(Cyclohexylmethoxy)-5-iodo-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine (81). A 
solution of 79 (0.112 g, 0.31 mmol) in THF (4 mL) containing diiodomethane (123 µL, 1.50 mmol), 
CuI (59 mg, 0.31 mmol), and isoamyl nitrite (187 µL, 0.92 mmol) was heated to reflux for 4 h, and 
the dark brown solution was filtered (Celite) and extracted with EtOAc (2 × 20 mL). The combined 
organic fraction was washed sequentially with aqueous sodium thiosulfate solution (10%, 2 × 40 
mL) and brine (40 mL), dried (MgSO4), and the solvent was removed in vacuo. Purification by 
chromatography (silica; 30% EtOAc:petrol) afforded 81 as a yellow oil (64 mg, 44%); Rf 0.19 (30% 
EtOAc:petrol); UV λmax (EtOH) 262 nm; IR (cm
-1) 3333, 2951, 2891, 2122, 1672, 1584, 1521; 1H 
NMR (500 MHz, DMSO-d6) δ 0.98-1.89 (11H, m, cyclohexyl), 3.71 (3H, s, OCH3), 4.19 (2H, d, J 
= 6.5 Hz, OCH2), 5.17 (2H, s, CH2), 6.90 (2H, d, J = 8.7 Hz, H-2'' and H-6''), 7.18 (1H, s, H-5), 
7.26 (2H, d, J = 8.8 Hz, H-3'' and H-5''), 8.31 (1H, s, H-2); 13C NMR (125 MHz, DMSO-d6) δ 25.1 
(CH2), 25.9 (CH2), 28.9 (CH2), 37.0 (CH), 45.8 (Ar-CH2), 55.1 (CH3), 74.4 (CH2), 112.0 (Ar-C), 
112.7 (Ar-C), 114.1 (Ar-C), 124.6 (Ar-C), 128.8 (Ar-C), 129.0 (Ar-C), 142.6 (Ar-C), 148.5 (Ar-C), 
157.0 (Ar-C), 158.8 (Ar-C); HRMS calcd for C21H25IN3O2 [M+H]
+
 478.0986, found 478.0980. 
4-((7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-yl) 
amino)benzenesulfonamide (82). To a solution of 81 (0.048 g, 0.10 mmol) in anhydrous MeCN (2 
mL) was added sulfanilamide (19 mg, 0.11 mmol), anhydrous K2CO3 (28 mg, 0.20 mmol), 
Pd2(dba)3 (2.3 mg, 0.004 mmol) and XPhos (1.9 mg, 0.004 mmol). The reaction mixture was 
degassed under N2 for 30 min, and stirred at 80 
oC for 2 h. The cooled solution was filtered (Celite) 
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extracted with EtOAc (2 × 20 mL), and the combined organic extract was washed sequentially with 
aqueous HCl (1 M, 20 mL), saturated aqeuous NaHCO3 (20 mL), and brine (30 mL), dried 
(Na2SO4), and the volatiles were evaporated in vacuo. Purification by chromatography (silica; 70% 
EtOAc:petrol) yielded 82 as a white solid (23 mg, 43%); Rf 0.59 (70% EtOAc:petrol); mp 142 
oC; 
UV λmax (EtOH) 257 nm; IR (cm
-1) 3329, 2933, 2874, 2158, 1662, 1588, 1501; 1H NMR (500 MHz, 
CDCl3) δ 1.00-1.97 (11H, m, cyclohexyl), 3.79 (3H, s, OCH3), 4.01 (2H, d, J = 6.1 Hz, OCH2), 4.76 
(2H, br s, NH2), 5.28 (2H, s, CH2), 6.17 (1H, s, H-5), 6.79 (1H, br s, NH), 6.88 (2H, d, J = 8.8 Hz, 
H-2'' and H-6''), 7.24 (2H, d, J = 8.7 Hz, H-3'' and H-5''), 7.61 (2H, J = 8.8 Hz, H-2' and H-6'), 7.81 
(2H, J = 8.8 Hz, H-3' and H-5'), 8.11 (1H, s, H-2); 13C NMR (125 MHz, CDCl3) δ 25.7 (CH2), 26.4 
(CH2), 29.8 (CH2), 37.6 (CH2), 46.9 (CH), 55.4 (CH2), 74.8 (OCH3), 90.7 (OCH2), 114.3 (Ar-C), 
117.1 (Ar-C), 128.0 (Ar-C), 129.1 (Ar-C), 139.7 (Ar-C), 145.5 (Ar-C), 152.1 (Ar-C); HRMS calcd 
for C27H32N5O4S [M+H]
+
 522.2170, found 522.2166. 
4-((7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-yl)amino) benzenesulfonamide (83). A 
solution of 82 (0.022 g, 0.042 mmol) in TFA (1 mL) was heated under reflux for 2 h, and the cooled 
solution was neutralised with saturated aqueous NaHCO3 (25 mL). The reaction mixture was 
extracted with EtOAc (3 × 30 mL), and the combined organic fraction was dried (MgSO4) and 
evaporated under reduced pressure. The title compound was purified by preparative TLC on silica, 
using 5% MeOH:DCM as eluent, to afford 83 as a white solid (16.7 mg, 99%); Rf 0.25 (5% 
MeOH:DCM); mp 165-166 oC; UV λmax (EtOH) 324, 274 nm; IR (cm
-1) 3332, 2925, 2852, 2164, 
1677, 1583, 1500; 1H NMR (500 MHz, MeOD-d4) δ 1.07-2.05 (11H, m, cyclohexyl), 4.03 (2H, d, J 
= 6.2 Hz, OCH2), 6.33 (1H, s, H-5), 7.77 (2H, d, J = 8.9 Hz, H-2' and H-6'), 7.92 (2H, d, J = 8.8 Hz, 
H-3' and H-5'), 7.96 (1H, s, H-2); 13C NMR (125 MHz, CDCl3) δ 26.9 (CH2), 27.6 (CH2), 30.8 
(CH2), 38.9 (CH), 74.9 (CH2O), 90.9 (Ar-C), 117.9 (Ar-C), 128.2 (Ar-C); HRMS calcd for 
C19H24N5O3S [M+H]
+
 522.2170, found 522.2166; HPLC: >98%, XSELECT column, retention time 
5.47 min, reverse phase, H2O/MeCN/ HCOOH gradient run, 1 mL min
−1. 
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7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (86). Prepared in 
accordance with general procedure C from 84 (1.50 g, 8.82 mmol). Precipitation from aqueous 
AcOH, and repeated washing with water, gave 86 a pale orange solid (1.52 g, 70%); mp 214-216 
oC; UV λmax (EtOH) 285 nm; IR (cm
-1) 3494, 3378, 2925, 2780, 2651, 2362, 2329, 2115, 2085, 
2013, 1906, 1628, 1608, 1578, 1488; 1H NMR (500 MHz, DMSO-d6) δ 1.03-1.89 (11H, m, 
cyclohexyl), 4.30 (2H, d, J = 6.5 Hz, OCH2), 6.91 (2H, br s, NH2), 15.28 (1H, br s, NH); 
13C NMR 
(125 MHz, DMSO-d6) δ 25.1 (CH2), 25.9 (CH2), 29.1 (CH2), 36.6 (CH), 71.2 (CH2), 162.2 (Ar-C);  
HRMS calcd for C11H17N6O [M+H]
+
  249.1458, found 249.1461. 
4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (87). Prepared according to the 
general procedure C from 85 (0.125 g, 0.74 mmol). Purification by chromatography (silica; 10% 
MeOH:DCM) gave 87 as an off white crystalline solid (68 mg, 37%); Rf 0.70 (10% MeOH:DCM), 
mp 193-195 oC; UV λmax (EtOH) 275 nm; IR (cm
-1) 3498, 3353, 3232, 3121, 2960, 2921, 2851, 
2750, 2667, 2158, 2038, 1902, 1794, 1633, 1578, 1497 ,1469, 1441; 1H NMR (500 MHz, DMSO-
d6) δ 0.98-1.82 (11H, m, cyclohexyl), 4.21 (2H, d, J = 6.5 Hz, OCH2), 6.55 (2H, br s, NH2), 7.77 
(1H, s, CH), 12.78 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.1 
(CH2), 36.7 (CH), 70.5 (CH2), 95.4 (Ar-C), 131.6 (Ar-C), 158.9 (Ar-C), 162.0 (Ar-C), 163.4 (Ar-
C);  HRMS calcd for C12H18N5O [M+H]
+
  248.1506, found 248.1508. 
5-Chloro-7-(cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (88). To a solution of LiCl 
(34 mg, 0.80 mmol) in DMA (0.5 mL) at 0 oC, was added 86 (0.05 g, 0.20 mmol), followed by 
isoamyl nitrite (61 µL, 0.30 mmol) and SOCl2 (16 µL, 0.22 mmol). The reaction mixture was 
stirred for 1 h, and allowed to warm to ambient temperature over 18 h. After addition of saturated 
aqueous NaHCO3 (15 mL), the reaction mixture was extracted with EtOAc (3 × 15 mL), and the 
combined organic layers were washed with brine (2 × 30 mL), dried (Na2SO4). Evaporation of the 
solvent under reduced pressure furnished 88 as a brown oil (54 mg, >99 %) which was used directly 
without further purification.  
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6-Chloro-4-(cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine (89). To a solution of LiCl (69 
mg,1.62 mmol) in DMA (1 mL) at 0 oC was added 87 (0.100 g, 0.40 mmol), followed by isoamyl 
nitrite (123 µL, 0.61 mmol) and SOCl2 (32 µL, 0.45mmol). The reaction mixture was stirred at 
room temperature for 18 h, cooled, and EtOAc (45 mL) was added. The resultant solution was 
washed sequentially with aqueous saturated NaHCO3 solution (45 mL) and brine (2 × 45 mL), dried 
(Na2SO4) and the volatiles were evaporated under reduced pressure. The product was purified by 
chromatography (silica; 5% MeOH:DCM) to give 89 as a yellow solid (65 mg, 60%); Rf 0.32 (5% 
MeOH:DCM), mp 152-153 oC; UV λmax (EtOH) 252 nm; IR (cm
-1) 3148, 2922, 2851, 1677, 1579, 
1443; 1H NMR (500 MHz, CDCl3) δ 0.96-1.95 (11H, m, cyclohexyl), 4.39 (2H, d, J = 6.0 Hz, 
OCH2), 8.09 (1H, s, CH), 11.19 (1H, br s, NH); 
13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 
(CH2), 29.1 (CH2), 36.7 (CH), 70.5 (CH2O), 95.4 (Ar-C), 131.6 (C
1-H), 158.9 (Ar-C), 162.0 (Ar-C), 
163.4 (Ar-C); HRMS calcd for C12H16ClN4O [M+H]
+
  267.1007, found 267.1012. 
4-((7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)amino) 
benzenesulfonamide (90). The title compound was prepared following general procedure A from 
88 (0.054 g, 0.20 mmol) and isolated by chromatography (silica; 30% EtOAc:petrol) to give the title 
compound 90 as a white solid (28 mg, 35%); Rf 0.18 (70% EtOAc:petrol); mp 217-219 
oC; UV λmax 
(EtOH) 310 nm; IR (cm-1) 3254, 3121, 2924, 2851, 2363, 2342, 2199, 2140, 1992, 19118, 1700, 
1582, 1534, 1492, 1447; 1H NMR (500 MHz, DMSO-d6) δ 1.04-1.92 (11H, m, cyclohexyl), 4.36 
(2H, d, J = 6.8 Hz, OCH2), 7.18 (2H, br s, SO2NH2), 7.72 (2H, d, J = 8.8 Hz, H-2' and H-6'), 7.99 
(2H, d, J = 9.0 Hz, H-3' and H-5'), 9.92 (1H, br s, NH) 13.34 (1H, br s, NH); 13C NMR (125 MHz, 
DMSO-d6) δ 25.1 (CH2), 29.1 (CH2), 35.9 (CH), 118.0 (Ar-C), 126.4 (Ar-C);  HRMS calcd for 
C17H22N7O3S [M+H]
+
  404.1499, found 404.1500; HPLC: >99.5%, XTerra column, retention time 
11.64 min, reverse phase, H2O/MeCN/ HCOOH gradient run, 1 mL min
−1. 
4-((4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)benzenesulfonamide 
(91). The title compound was prepared by general procedure A from 89 (0.042 g, 0.18 mmol). 
Chromatography (silica; 70% EtOAc:petrol) afforded 91 as a  white solid (20 mg, 28%); Rf 0.21 
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(70% EtOAc:petrol), mp 268-269 oC; UV λmax (EtOH) 304 nm; IR (cm
-1) 3367, 3333, 3269, 2922, 
2853, 2162, 2012, 1691, 1658, 1624, 1583, 1551, 1524; 1H NMR (500 MHz, DMSO-d6) δ 1.04-
1.92 (11H, m, cyclohexyl), 4.36 (2H, d, J = 6.8 Hz, OCH2), 7.18 (2H, br s, SO2NH2), 7.72 (2H, d, J 
= 8.8 Hz, H-2' and H-6'), 7.98 (1H, br s, CH), 7.99 (2H, d, J = 9.0 Hz, H-3' and H-5'), 9.92 (1H, br 
s, NH) 13.34 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.4 (CH2), 26.5 (CH2), 29.5 
(CH2), 37.1 (CH), 71.5 (CH2) 118.6 (Ar-C), 136.6 (Ar-C), 144.0 (Ar-C);  HRMS calcd for 
C18H23N6O3S [M+H]
+
  403.1547, found 403.1547; HPLC: >98.5%, XTerra column, retention time 
11.92 min, reverse phase, H2O/MeCN/ HCOOH gradient run, 1 mL min
−1. 
4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (93). Prepared in accordance with 
general method C from 92 (0.15 g, 0.89 mmol), with heating under microwave irradiation (170 oC, 
5 h). The product was isolated by chromatography (silica; 10% MeOH:DCM) to yield 93 as a white 
crystalline solid (37 mg, 17%); Rf 0.55 (10% MeOH:DCM); mp 216.3-217.3 
oC; UV λmax (EtOH) 
221 nm; IR (cm-1) 3494, 3362, 3117, 2922, 2851, 2164, 2045, 1968, 1617, 1585, 1499, 1478; 1H 
NMR (500 MHz, DMSO-d6) δ 0.98-1.83 (11H, m, cyclohexyl), 4.15 (2H, d, J = 6.5, OCH2), 5.91 
(2H, br s, NH2), 6.17 (1H, dd, J = 1.9 and 3.5, CH), 6.79 (1H, dd, J = 2.2 and 3.5, HNCH), 10.97 
(1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.3 (CH2), 36.8 (CH), 
69.9 (CH2O), 96.9 (C
1-H), 97.9 (Ar-C), 119.1 (C2-H), 155.0 (Ar-C), 159.3 (Ar-C), 162.7 (Ar-C); 
HRMS calcd for C13H19N4O  [M+H]
+ 247.1553, found 247.1556. 
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (94). NaH 
(60% in mineral oil, 26 mg, 0.65 mmol) was added dropwise to a solution of 92 (0.10 g, 0.59 mmol) 
in anhydrous MeCN (3 mL) at -30 oC, and the reaction mixture was stirred for 45 min. 2-
(Trimethylsilyl)ethoxymethyl chloride (90%, 122 µL, 0.62 mmol) was added dropwise, and the 
reaction mixture was stirred for a further 3 h at room temperature. After cooling and addition of 
water (20 mL), the resultant solution was extracted with EtOAc (20 mL), and the combined organic 
fractions were washed with brine (3 × 20 mL), dried (Na2SO4), and the solvent was removed in 
vacuo. Purification by chromatography (silica; 15% EtOAc:petrol) gave 94 as a yellow solid (130 
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mg, 74%); Rf 0.41 (15% EtOAc:petrol); mp 63-64 
oC; UV λmax (EtOH) 317, 234 nm; IR (cm
-1) 
3423, 3318, 3212, 3096, 2952, 1631, 1608, 1546, 1493; 1H NMR (500 MHz, CDCl3) δ -0.04 (9H, s, 
(CH3)3), 0.91 (2H, t, J = 8.0 Hz, OCH2CH2Si), 3.81 (2H, t, J = 8.3 Hz, OCH2CH2Si), 4.96 (2H, br s, 
NH2), 5.44 (2H, s, CH2), 6.43 (1H, d, J = 3.7 Hz, CH), 6.99 (1H, d, J = 3.7 Hz, NCH);
 13C NMR 
(125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 19.2 (CH2CH2Si), 67.7 (OCH2CH2), 74.3 (NCH2O), 102.2 
(C5H), 112.2 (Ar-C), 127.0 (C6H), 154.2 (Ar-C), 155.6 (Ar-C), 160.2 (Ar-C); HRMS calcd for 
C12H20ClN4OSi [M+H]
+
  299.1089, found 299.1090. 
4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
amine (95). Synthesised following general procedure C from 94 (0.30 g, 1.01 mmol), except 
using THF as solvent. The title compound was isolated by chromatography (silica; 15% 
EtOAc:petrol) to furnish 95 as a yellow solid (296 mg, 78%); Rf 0.17 (15% EtOAc:petrol); mp 88-
90 oC; UV λmax (EtOH) 286, 260, 223 nm; IR (cm
-1) 3346, 3222, 2926, 2852, 1647, 1602; 1H NMR 
(500 MHz, CDCl3) δ -0.05 (9H, s, (CH3)3), 0.91 (2H, t, J = 8.3 Hz, OCH2CH2Si), 1.01-1.91 (11H, 
m cyclohexyl), 3.51 (2H, t, J = 8.3 Hz, OCH2CH2Si), 4.21 (2H, d, J = 6.5 Hz, OCH2), 4.68 (2H, br 
s, NH2), 5.41 (2H, s, CH2), 6.40 (1H, d, J = 3.7 Hz, CH), 6.82 (1H, d, J = 3.7 Hz, NCH); 
13C NMR 
(125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 19.2 (CH2CH2Si), 27.2 (CH2), 28.0 (CH2), 31.3 (CH2), 38.8 
(CH), 67.4 (OCH2CH2), 72.6 (CH2), 74.1 (NCH2O), 101.2 (C
5H), 123.6 (C6H), 160.6 (Ar-C), 165.4 
(Ar-C); HRMS calcd for C19H33N4O2Si [M+H]
+
  377.2367, found 377.2367. 
2-Chloro-4-(cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidine (96). To a solution of LiCl in THF (0.5 M, 2.13 mL, 1.1 mmol) was added 95 (0.10 g, 
0.27 mmol) and the reaction mixture was cooled to 0 oC. Isoamyl nitrite (81 µL, 0.40 mmol) and 
SOCl2 (21.3 µL, 0.29 mmol) were added, and the solution was stirred at room temperature for 5 h. 
The reaction mixture was added to a solution of aqueous NH4Cl (2 M, 30 mL), extracted with 
EtOAc (2 × 30 mL), and the combined organic layers were washed with water (3 × 30 mL), dried 
(Na2SO4), and evaporated in vacuo. Purification by chromatography (silica; 15% EtOAc:petrol) 
gave 96 as a clear oil (60 mg, 56%); Rf 0.45 (15% EtOAc:Petrol); UV λmax (EtOH) 270 nm; IR (cm
-
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1) 2924, 2852, 1750, 1661, 1588, 1558, 1506; 1H NMR (500 MHz, DMSO-d6) δ -0.09 (9H, s, 
(CH3)3), 0.82 (2H, t, J = 8.1 Hz, OCH2CH2Si), 0.95-1.89 (11H, m cyclohexyl), 3.50 (2H, t, J = 8.1 
Hz, OCH2CH2Si), 4.28 (2H, d, J = 6.0 Hz, OCH2), 5.52 (2H, s, CH2), 6.61 (1H, d, J = 3.6 Hz, CH), 
7.55 (1H, d, J = 3.5 Hz, NCH); 13C NMR (125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 18.5 
(CH2CH2Si), 26.6 (CH2), 30.5 (CH2) 31.8 (CH2), 38.8 (CH), 67.1 (OCH2CH2), 73.3 (CH2), 74.2 
(NCH2O), 100.4 (C
5H), 126.4 (C6H), 129.7 (Ar-C); HRMS calcd for C19H31ClN3O2Si [M+H]
+
  
396.1869, found 396.1872. 
4-((4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-
2-yl)amino)benzenesulfonamide (97). To a degassed solution of 96 (0.050 g, 0.13 mmol) in 
MeCN (2 mL) was added sulfanilamide (24 mg, 0.14 mmol), anhydrous K2CO3 (35 mg, 0.25 
mmol), Pd2(dba)3 (3 mg, 5.0 x 10
-3 mmol) and XPhos (2.4 mg,  5.0 x 10-3 mmol), and the reaction 
mixture was stirred under N2 at 80 
oC for 2 h. The cooled mixture was filtered (Celite), diluted with 
EtOAc (20 mL), and washed sequentially with aqueous HCl solution (1 M, 20 mL), saturated 
aqueous NaHCO3 solution (20 mL), and brine (30 mL). After drying (Na2SO4), volatiles were 
removed under reduced pressure, and the product was isolated by chromatography (silica; 50% 
EtOAc:petrol) to give 97 as a yellow oil (33 mg, 49%); Rf 0.63 (50% EtOAc:petrol); UV λmax 
(EtOH) 269 nm; IR (cm-1) 3644, 3342, 2924, 2853, 1586, 1528, 1488; 1H NMR (500 MHz,CDCl3) 
δ -0.08 (9H, s, Si(CH3)3), 0.88-0.95 (2H, t, J = 8.36 Hz, OCH2CH2Si) 1.04-1.93 (11H, m, 
cyclohexyl), 3.56 (2H, t, J = 3.4 Hz, OCH2CH2Si) 4.29 (2H, d, J = 6.5 Hz, OCH2), 4.72 (2H, br s, 
NH2), 5.52 (2H, s, CH2), 6.49 (1H, d, J = 3.5 Hz, CH), 6.96 (1H, d, J = 3.6 Hz, NCH), 7.20 (1H, br 
s, NH), 7.87 (4H, ap s, H-2', H-3', H-5' and H-6'); 13C NMR (125 MHz, CDCl3) δ 0.0 (SiCH3), 15.6 
(CH2Si), 27.2 (CH2), 27.9 (CH2), 31.3 (CH2), 38.8 (CH), 67.8 (CH2), 73.2 (CH2), 74.5 (CH2), 101.5 
(Ar-C), 101.9 (Ar-C), 118.8 (Ar-C), 125.0 (Ar-C), 129.3 (Ar-C), 146.2 (Ar-C); HRMS calcd for 
C25H38N5O4SSi [M+H]
+
  532.2408, found 532.2406. Note: not all carbons are visible.  
4-((4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)benzenesulfonamide (98). 
A solution of 97 (0.040 g, 7.5 x 10-2 mmol) in TFA (1.5 mL) was heated under reflux for 10 min., 
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and the cooled solution was neutralised with saturated aqueous NaHCO3 solution. The aqueous 
solution was extracted with EtOAc (2 × 30 mL), and the solvent was evaporated under reduced 
pressure. The residual yellow solid was redissolved in MeCN:H2O (1:1, 8 mL), the pH of the 
solution was adjusted to 10 with dilute aqueous ammonia (28%), and the solution was stirred for 1 h 
at room temperature and evaporated in vacuo. Isolation by chromatography (silica; 70% 
EtOAc:petrol) to give 98 as a white solid (12 mg, 40%); Rf 0.39 (70% EtOAc:petrol); mp 251.2-
252.0 oC; UV λmax (EtOH) 312 nm; IR (cm
-1) 3374, 3322, 2058, 2924, 2856, 2012, 1615, 1595, 
1579; 1H NMR (500 MHz, DMSO-d6) δ 1.07-1.95 (11H, m, cyclohexyl), 4.31 (2H, d, J = 6.3 Hz, 
OCH2), 6.34 (1H, dd, J = 2.1 and 2.1 Hz, CH), 7.05 (1H, dd, J = 2.2 and 2.2 Hz, HNCH), 7.13 (2H, 
br s, SO2NH2), 7.68 (2H, d, J = 8.9 Hz, H-2' and H-6') 7.99 (2H, d, J = 8.8 Hz, H-3' and H-5'), 9.57 
(1H, br s, NH), 11.54 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 
29.3 (CH2), 36.8 (CH), 70.6 (CH2), 98.2 (C
5H), 116.9 (Ar-C), 126.4 (C6H), 134.9 (Ar-C), 144.6 
(Ar-C), 146.4 (Ar-C), 153.6 (Ar-C), 154.4 (Ar-C), 162.4 (Ar-C); HRMS calcd for C19H24N5O3S 
[M+H]+  402.1594, found 402.1596; HPLC: >99.5%, XSELECT column, retention time 8.45 min, 
reverse phase, H2O/MeCN/ HCOOH gradient run, 1 mL min
−1. 
7-Chloro-5-cyclohexylmethoxyimidazo[1,2-a]pyrimidine (100). Synthesised in accordance with 
general procedure C from 99 (1.0 g, 5.4 mmol). The product was purified by precipitation with 
glacial acetic acid, and repeated washing with water, to afford 100 as a pale orange powder (1.16 g, 
81%); Rf 0.23 (60% EtOAc:petrol); 
1H NMR (300 MHz, DMSO-d6) δ 1.05-1.95 (11H, m, 
cyclohexyl), 4.30 (2H, d, J = 6.1 Hz, OCH2), 6.63 (1H, s, H-6), 7.63 (2H, d, J = 1.2 Hz, H-3), 7.81 
(2H, d, J = 1.3 Hz, H-2); 13C-NMR (75 MHz, DMSO-d6) δ 25.4, 26.2, 29.0, 36.9, 76.3, 88.8, 107.6, 
134.2, 148.1, 152.1, 155.6; LRMS (ES+) m/z 266.0 [M+H]+. 
5-Cyclohexylmethoxy-7-anilinoimidazo[1,2-a]pyrimidine (101). The title compound was 
synthesised according to general procedure A from 100 (0.075 mg, 0.28 mmol). Purification by 
chromatography (silica; EtOAc), followed by crystallisation from MeOH, gave 101 (31 mg, 34%); 
Rf 0.11 (100% EtOAc); mp 252-253 °C; UV λmax (EtOH) 305, 257, 212 nm; IR (cm
-1) 3153, 2926, 
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2847, 2161, 1627, 1595, 1568, 1531, 1489, 1291, 1259, 1122; 1H NMR (300 MHz, DMSO-d6) δ 
1.05–1.85 (11H, m, cyclohexyl), 4.35 (2H, d, J = 6.2 Hz, OCH2), 5.98 (1H, s, H-6), 6.99 (1H, t, J = 
7.3 Hz, PhH), 7.26 (1H, d, J = 1.6 Hz, H-3), 7.33 (2H, dd, J = 7.6, 8.2 Hz, 2 × PhH), 7.44 (1H, d, J 
= 1.6 Hz, H-2), 7.83 (2H, d, J = 7.7 Hz, 2 × PhH), 9.45 (1H, s, NH); LRMS (ES+) m/z 323.0 
[M+H]+; Anal. Found: C, 70.41; H, 6.59; N, 17.40. C19H22N4O requires C, 70.78; H, 6.88; N, 
17.38%. 
5-Cyclohexylmethoxy-7-(4’-sulfamoylanilino)imidazo[1,2-a]pyrimidine (102). Prepared in 
accordance with general procedure A from 100 (0.25 g, 0.94 mmol), and purified by 
chromatography (silica; 5% MeOH:EtOAc) to give 102 as a colourless solid (28 mg, 7%); Rf 0.47 
(10% MeOH:EtOAc); mp 228-229 °C; IR (cm-1) 3348, 3292, 2926, 2847, 1653, 1617, 1591, 1536, 
1429, 1310, 1155; UV λmax (EtOH) 315, 266, 216 nm; 
1H NMR (300 MHz, DMSO-d6) δ 1.15-1.90 
(11H, m, cyclohexyl), 4.16 (2H, d, J = 6.1 Hz, OCH2), 6.03 (1H, s, H-6), 7.24 (2H, s, SO2NH2), 
7.32 (1H, d, J = 1.6 Hz, H-3), 7.51 (1H, d, J = 1.6 Hz, H-2), 7.78 (2H, d, J = 8.9 Hz, H-2' and H-6'), 
7.99 (2H, d, J = 8.9 Hz, H-3' and H-5'), 9.85 (1H, s, NH). 13C-NMR (75 MHz, DMSO-d6) δ 25.45, 
26.19, 29.16, 36.85, 75.00, 78.91, 105.83, 118.42, 127.05, 131.95, 137.03, 144.01, 154.73, 155.68. 
LRMS (ES+) m/z 402.0 [M+H]+; Anal. Found: C, 57.06; H, 5.53; N, 17.09. C19H23N5O3S requires 
C, 56.84; H, 5.77; N, 17.44%. 
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Protein kinase assays 
Human CDK1/B was purchased from New England Biolabs or prepared as described, 46  CDK2/A2 
was prepared as described, 46 CDK4/D was provided by AstraZeneca and CDK7/H and CDK9/T 
were purchased from Upstate. IC50 values for CDK1/B, CDK2/A and CDK4/D were determined as 
described. 23 IC50 values for CDK7/H and CDK9/H were determined according to the Supplier’s 
instructions (Upstate). CDK1/B, CDK2/A and CDK4/D were assayed at an ATP concentration of 
12.5 µM, CDK7/H and CDK9/T at an ATP concentration of 100 µM. Published Km(ATP) values 
for CDK1-cyclin B, CDK2-cyclin A, CDK4-cyclin D2, CDK7-cyclin H-MAT and CDK9-cyclin T 
are 0.8 µΜ, 0.58 µM, 3.8 µM, 4.1 µM and 0.7 µM respectively (www.proqinase.com).         
Growth inhibition assays 
The ability of selected compounds to inhibit cell growth was assessed in a panel of human cancer 
cell lines using an SRB assay. 45 Briefly, cells in 96-well plates were exposed to inhibitor (0.1-30 
µM, 3 replicates per drug concentration) or 0.5 % (v/v) DMSO (for compound 73 treatments) or 
0.1% (v/v) DMSO (for all other inhibitors) for 120 h, stained with sulforhodamine B and the 
absorbance at 570 nm measured (SpectraMax®250; Molecular Devices, Wokingham, UK). At least 
three independent experiemnts were performed. Growth inhibitory GI50 values were calculated 
using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). 
Crystallisation and structure determination 
Crystals of CDK2-cyclin A bound to 73 and CDK1–cyclin B-CKS2 bound to 3 were grown as 
previously described. 46  Briefly, the inhibitors were added in twofold molar excess (which was also 
a 10-fold higher concentration than the inhibitor IC50) to a low concentration solution of the 
appropriate protein complex and then the samples were concentrated to 10–12 mg ml-1 for 
crystallization. CDK2-cyclin A-73 crystals were grown from a well solution containing 0.6–0.8 M 
KCl, 0.9–1.2 M (NH4)2SO4, and 100 mM HEPES (pH 7.0). CDK1-cyclin B-CKS2 was co-
crystallised with 3 from a screen covering the conditions 0.1 M MES/imidazole buffer (pH 6.7), 
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6.5% MPD, 5% PEG4K, 10% PEG1K. Before data collection, crystals were cryoprotected by brief 
immersion in either 8 M sodium formate (CDK2-cyclin A) or 25% ethyleneglycol (CDK1-cyclin B-
CKS2). 
Data processing was carried out using XDS, MOSFLM, POINTLESS/AIMLESS 52 and other 
programs of the CCP4 suite, 53 run through the CCP4i2 GUI. 54 The structures of the different 
complexes were solved by molecular replacement using Phaser, 55 and search models drawn from 
PDB entries 1QMZ (cyclin A-bound CDK2) and 4Y72 (CDK1-cyclin B-CKS2). Models of 73 and 
3 and ligand restraints were generated using ACEDRG within the CCP4i2 suite, 54 and built into the 
electron density using Coot. 56 Structures were refined using REFMAC, 57 interspersed with manual 
rebuilding in Coot, including TLS refinement.  
 
Accession Codes 
CDK2-cyclin A in complex with compound 73 (5LQE), and CDK1-cyclin B-CKS2 in complex 
with compound 3 (5LQF) have been deposited with the PDB and the atomic coordinates and 
experimental data will be released upon article publication. 
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